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ABSTRACT
In genetic epidemiology studies of complex traits, there are two main design types through
which we can study complex traits. The first is population-based, in which independent
cases and controls are collected to assess the difference in the underlying genetic makeup
between affected and unaffected individuals. The other is family-based, in which data from
families with at least one affected individual are collected. This allows for the study of the
transmission of genetic variants between parent and offspring and how genetic variants differ
between the affected individual(s) and the unaffected individuals within a family.
We examine two hallmarks of complex traits in this dissertation. The first is the combina-
tion of mixed data types into a single likelihood, leveraging assumptions about the genotype
frequencies to the extent that the data support them. To do this we will employ an em-
pirical Bayes-type shrinkage estimation approach. Combining multiple data structures into
a robust joint analysis may provide additional information about the disease loci driving
complex traits. Secondly, we will examine heterogeneous presentation of traits associated
with complex disorders. This phenotypic heterogeneity may arise due to genetic underpin-
nings, different environmental exposures, or perhaps by unknown factors. Specifically, we
will address the following questions: (1) How can family data be combined with case-control
data from the same study to improve estimates of disease association in a way that is ro-
bust to model misspecification? (2) How can genetic sources of phenotypic heterogeneity be
identified in case-control and family-based studies?
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The public health significance of this research is that these methods will further under-
standing of the genetic architecture and will provide framework for studying other complex
traits. Knowing the underlying genetic structure of a complex disease like orofacial cleft-
ing will aid in identifying any possible modifiable environmental factors that may also be
contributing to the etiology of the disease. In order to identify those factors, we must have
foundational knowledge of the biologic mechanism through which OFCs arise.
Keywords: genome-wide association study, empirical Bayes-type estimation, shrinkage es-
timation, phenotypic heterogeneity, complex traits.
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1.0 INTRODUCTION
The goal of genetic studies is to further understand the mechanisms contributing to a phe-
notype by measuring association between genetic variants and the phenotype in some pop-
ulation. Genome-wide association studies (GWAS) aim to do so by assessing the effect of
single-nucleotide polymorphisms (SNPs) on a trait statistically. Traditionally, an associa-
tion test is performed at every genetic marker genome-wide and the markers demonstrating
the most statistical significance are considered for further interrogation. These associations
identify candidate loci for genetic association with the trait. Importantly, these associations
are not necessarily causal, as statistical power is influenced by the allele frequency. Rather,
markers implicated in association studies are thought to be in linkage disequilibrium (i.e.
correlated) with true causal genetic marker(s).
The power of GWAS to identify a true association between a SNP and trait is depen-
dent on the variability present in the phenotype and how much of that variability can be
explained by the SNP [35]. The variability in the phenotype is determined by the effect size
of the variant and the allele frequencies in the sample. Because of this, analyzing both rare
variants and variants with small effect size can pose problems in GWAS. Additionally, sta-
tistical power to detect association between a genetic marker and a phenotype is decreased
as phenotypic variation which is not directly attributable to the genetic variant increases.
This is common in complex diseases which typically have heterogeneous presentations.
Furthermore, some traits are driven by a few loci with large effect sizes, whereas others
are controlled by more genetic loci and numerous factors including admixture, epistasis, and
environmental exposures. Investigating complex architectures requires examining population
structure and potential allele-frequency differences across populations. Spurious associations
can occur for SNPs with varying allele frequencies and trait distributions by population by
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population [35]. Additionally, investigation of potential gene-by-gene interactions (i.e. epis-
tasis) and gene-by-environment interactions is warranted. These interactions occur when
the effect a genetic locus has on a trait is modified by either another genetic locus (gene-
by-gene interaction) or an external environmental factor (gene-by-environment interaction).
These complexities in genetic architecture present challenges in GWAS. There are virtu-
ally endless possibilities for the underlying genetic model of complex traits. These models
can include any of the considerations mentioned above, including but not limited to rare
variant contributions, differing effect sizes, population differences, gene-by-gene interactions,
and gene-by-environment interactions. Assessing a genetic variant’s association with a trait
having complex genetic architecture presents an interesting challenge.
There are two primary sampling schemes for GWAS. The first is population-based, com-
prised of unrelated individuals; the second is family-based, consisting of related individuals.
Although these structures are traditionally viewed as separate analyses, they may be com-
bined as mixed data structure and analyzed together. Family-based studies are unique in
that they are robust against population stratification; spurious statistical associations due
to differences in allele frequencies across populations are generally not discovered in family-
based samples [27]. These data structures also allow for the study of transmission of alleles
from parent to offspring. In contrast, the traditional epidemiological population-based study
design is easy to implement as it does not require recruitment of every individual of inter-
est from within a family. Moreover, population-based designs are more powerful to detect
common, weak genetic associations [66].
We will investigate two of the considerations discussed above – examining heterogeneous
phenotypes and mixing data structures from population-based and family-based collection
methods. Mixed data structures are being used increasingly in the study of complex traits
because they offer the advantages of both population-based and family-based designs with-
out limiting the study with the disadvantages that come with selecting only one method
[29]. As mentioned previously, phenotypic heterogeneity is a hallmark of complex traits and
can reduce the ability to detect true genetic associations. However, there may be genetic
differences responsible for the variability in phenotype, the identification of which would
further elucidate the genetic underpinnings of complex traits. This dissertation addresses
2
the philosophical and statistical considerations for mixing data structures and addressing
phenotypic heterogeneity.
1.1 MIXED DATA STRUCTURES
Genetic association studies can generally be divided into two main design types – population-
based studies and family-based studies. In the study of dichotomous traits, population-
based case-control designs, which directly compare the frequency of genetic variants between
(usually independent) cases and controls, are widely used for association studies. The goal
of these studies is to identify potential genetic loci with differential frequency between cases
and controls which may correspond to conferring disease risk. Case-control designs are
increasingly being used for GWAS due to the ease in recruitment and the decreasing cost of
genotyping large numbers of individuals [11] [36] [65].
Alternatives to case-control designs include various family-based designs, including the
case-parent trio design. The most common analysis technique with case-parent trios is
arguably the transmission/disequilibrium test (TDT). The TDT examines case-parent trios
in which the proband is an incident case [71]. In this situation, the allele at each locus of
interest (or genome-wide) is tested for whether the transmission of that allele from parent to
offspring is different from what is expected under Mendelian inheritance (i.e. each allele has
a 50% chance of being transmitted). This would provide evidence that cases are under/over
enriched for an allele due to the increased/decreased risk harbored by that variant.
The case-parent trio design is robust against population stratification as the methods
for analyzing such data include some form of conditioning on parental genotypes, which
eliminates potential bias from differing genetic background. In this setting, studying parents
provides perfectly matched controls for each incident case, and thus is robust to any existing
population substructure. However, case-parent trios are often difficult to collect as they
require the ascertainment of both DNA specimens and phenotyping for each member of the
trio. Moreover, the cost of genotyping trios is three times that for each case or control
without a corresponding linear increase in statistical power.
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While population-based studies have increased statistical power over the family-based
designs of the same number of individuals, association signals detected from this method may
be due to uncontrolled confounding factors. In particular, case-control designs are susceptible
to confounding population stratification in which the genetic ancestry is associated with both
allele frequency and disease incidence.
Population-based data collection is frequently combined with family-based data collection
for many reasons. First, in an effort to gather as much information about a trait as possible,
genotypic and phenotypic information is often collected on every available person. Secondly,
and arguably most importantly, combining family-based data with population-based data
protects against false positive association due to population substructure. Thus, combining
these approaches offers increased statistical power and protection against false positives.
An overview of the basic analyses for case-control and case-parent trio designs and a brief
review of the available methods for combining these data together is given in chapter 2.
1.2 PHENOTYPIC HETEROGENEITY IN COMPLEX TRAITS
The model of Mendelian inheritance offers a simple explanation of the genetic architecture
of a trait. It prescribes that a single gene locus produces the trait in either recessive or
dominant pattern in families. However, many traits do not follow such a straightforward
model of genetic architecture.
Complex traits are those that do not exhibit classic Mendelian recessive or dominant
inheritance attributable to a single gene locus [36]. Any break in a direct genotype-phenotype
association (i.e. the same genotype resulting in different phenotypes, or different genotypes
resulting in the same phenotype) increases the genetic complexity of the trait. This can
be caused by numerous factors, including environmental exposures, interactions with other
genes, or even chance alone.
Variability in clinical and subclinical features, referred to here as phenotypic heterogene-
ity, is common in complex diseases and is thought to arise because of a complex genetic
and environmental architecture. Such variability introduces difficulty in studying complex
4
disease; it is unknown if slight variations in phenotype are caused by an unknown but identi-
fiable factor or if they carry identical risk factors and exhibit variation due to chance alone.
Environmental factors can harbor a large proportion of disease risk, as seen in many
complex traits including birth defects. While environmental factors contribute to etiology,
they do not completely explain the variability in complex traits, especially those with known
genetic risk loci. Further exploration of the genetic variation associated with phenotypic
variation, including the potential interactions between environmental and genetic factors, is
of public health significance.
Additionally, in studying the variable phenotypes associated with complex traits, many
distinct phenotypes are often collapsed into a broader phenotype to increase statistical power
for detection of genetic loci. However, the ability to capture genetic variation responsible for
subtle phenotypic variation is lost when nonhomogeneous features are misclassified as the
same disease. Furthermore, in order to identify all genetic factors contributing to disease, and
the mechanisms through which they interact to confer disease risk, these complex phenotypes
must be studied with more granularity.
Identifying genetic sources of phenotypic variation is vital in the study of complex traits,
as doing so will further the understanding of the mechanisms through which complex traits
arise.
1.3 OROFACIAL CLEFTS
Cleft lip with or without cleft palate (CL/P) is a common birth defect worldwide; it is the
most frequent craniofacial birth defect in humans. Approximately 1 in 800 live births has
CL/P; however, the birth prevalence of CL/P varies by different ethnic groups, geographic
locations and environmental exposures [64]. The highest incidence of CL/P was found in
Asian and American Indian populations, followed by Caucasian populations, with African
populations having the lowest incidence [76]. In developed countries, CL/P does not weigh
heavily on mortality, but does result in considerable morbidity, as well as economic and
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societal burden [75]. CL/P has severe consequences for affected individuals as it may inhibit
or disrupt speech, facial expression, and swallowing [79].
Individuals born with CL/P may experience problems with feeding, speaking, hearing
and socializing. These can be corrected to varying degrees by surgery, dental treatment,
speech therapy and psychosocial intervention [17]. Despite the availability of treatments,
CL/P impose a large financial and psychological aﬄiction on affected families and society
[79]. The cost per incident of CL/P is conservatively estimated to be $92,000 with a lifetime
cost of treatment of $200,000, which ignores the psychosocial costs to the patients and
occupational cost to parents [6] [39]. Children with CL/P also experience direct nonmedical
costs, such as special education services [6]. In addition to financial costs, there are physical
costs to children with CL/P; neonatal mortality is higher among children with CL/P [6].
CL/P arises when normal fetal craniofacial development fails. Cleft lip (CL) occurs when
the lip fails to fuse completely in the early stages of embryogenesis. Similarly, cleft palate
(CP) presents when the facial primordia, the building blocks of skulls, do not join properly.
The formation of the lip is completed by the sixth week of embryogenesis, while the formation
of the palate is completed by the thirteenth week [75]. A complex series of molecular events
must occur for proper facial development including cell growth, migration, differentiation,
and apoptosis (cell death) [39]. Similar to other congenital defects, this complex process
suggests a large genetic contribution to CL/P. However, the cause of CL/P is thought to be
a complex mixture of genetic predispositions and environmental exposures [64].
CL/P are considered nonsyndromic if they occur as the only abnormality; syndromic
clefts are defined as those accompanied by additional structural and/or developmental ir-
regularities [64]. In order to examine the etiology of orofacial clefts independent of other
disorders, only nonsyndromic clefts are studied. It is further noted that the majority (ap-
prox. 70%) of cases of CL/P are nonsyndromic [64]. Many previous GWASs have examined
the genetic role of CL/P, and many biologically plausible genes have been nominated in-
cluding IRF6, FGFR1, MAFB, ABCA4, VAX1, Wnt signaling, MSX1, and BMP [64] [17].
However, the complex etiology of CL/P remains poorly described.
CL and CP can occur unilaterally or bilaterally, concurrently or separately. Examples
of some possible types of CL/P are shown in Figure 1.1. CL and cleft lip and palate (CLP)
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have historically been considered variants of the same congenital defect, differing in severity
[51]. Despite the fact that CL and CLP have separate developmental geneses, they share a
defect in the primary palate, motivating the combined phenotype CL/P [39].
Figure 1.1: Images of CL/P (A) bilateral cleft lip (B) unilateral cleft lip and palate (C) cleft
palate
Clefts are usually regarded as simple, qualitative traits (unaffected vs. affected), al-
though the range of physical presentations is quite large. Recently, there has been evidence
suggesting that these overt clefts, in addition to subclinical phenotypes, lie on a continuum
of cleft features [80]. These subclinical phenotypes may be present in unaffected relatives
and would give additional genetic information about clefts overall [81]. While CL/P are
visible deformations of the face, these subclinical phenotypes include lip print whorls [58],
orbicularis oris (OO) muscle defects [57], and others [80]. Incorporation of these additional
phenotypes may aid in explaining the complex genetic architecture of CL/P.
1.4 MOTIVATING EXAMPLES
1.4.1 CleftSeq
The CleftSeq project was the first study to perform targeted sequencing of nonsyndromic
cleft lip with or without cleft palate (NSCL/P) GWAS regions. Through this we sequenced
complete GWAS intervals, including non-coding and coding DNA. The 13 regions that were
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sequenced were those that had been shown to be previously associated with OFCs. These 13
regions, totaling 6.3 Mb, were comprised of 9 high-priority candidates from previous GWAS
and/or genome-wide linkage studies and 4 regions containing candidate genes with prior
evidence of rare variants contributing to NSCL/P (Table 1.1). One thousand four hundred
and ninety-eight case-parent trios from Europe, the United States, China and the Philippines
were sequenced.
Because of the case-parent trio design, the transmission disequilibrium test was used
to determine if there was over-transmission of risk alleles for any variant. This method
is robust to population admixture. Still, we typically separate subpopulation groups for
analysis, testing for association separately for Europeans and Asians, as previous studies
have shown different association signals for NSCL/P in Asian and European populations.
Using this method, we found three regions for functional analysis follow-up (PAX7, FGFR2,
and NOG). We believe that this targeted sequencing of trios is powerful to identify functional
variants, i.e. genetic variants which alter the function of the gene.
We also identified strong associations in multiple regions with NSCL/P in the Asian trios,
but only in a single region, 8q24, in the European trios. Previous studies have shown associ-
ation with many other regions in Europeans, so this study may have been underpowered to
detect these. We hypothesized that many regions associated with NSCL/P are shared among
different populations, and that some regions have population-specific signals. However, these
hypotheses have not been rigorously tested.
Another reason that targeted sequencing was used is because it makes it possible to
search for the contributions of rare variants as risk alleles for NSCL/P. However, only 2 of
the 13 regions (near NOG and NTN1 ) showed any evidence of rare-variant over-transmission.
We hypothesized that we would see many more regions with over-transmitted rare variants
because of the nature of NSCL/P. Only about 50% of the heritability of NSCL/P is explained
by the previously discovered genes/loci, which suggests a substantial contribution of rare
variants. Notably, we did not see any rare variant signal in the four rare-variant candidate
regions (BMP4, FGFR2, MSX1, and PTCH1 ). The rare variants in this study were analyzed
with a burden-style test. This type of test cannot distinguish direction of effect or the
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difference between functional and non-functional variants, which leads to decreased power
to detect over-transmission in both of these situations.
Table 1.1: Overview of Regions Sequenced
Region Candidate Gene in Region Target Region [GRCh37] Size (kb)
1p36 PAX7 chr1: 18,772,300 - 19,208,054 435.8
1p22 ARHGAP29 chr1: 94,324,660 - 95,013,109 688.4
1q32 IRF6 chr1: 209,837,199 - 210,468,406 631.2
previous GWAS hits 8q24 – chr8: 129,295,896 - 130,354,946 1059.1
10q25 VAX1 chr10: 118,421,625 - 119,167,424 745.8
17p13 NTN1 chr17: 8,755,114 - 9,266,060 510.9
17p22 NOG chr17: 54,402,837 - 54,957,390 554.6
20q12 MAFB chr20: 38,902,646 - 39,614,513 711.9
previous linkage hit 9q22 FOXE1 chr9: 100,357,692 - 100,876,841 519.1
4p16 MSX1 chr4: 4,825,126 - 4,901,385 76.3
candidate gene 9q22 PTCH1 chr9: 98,133,647 - 98,413,162 279.5
regions 10q26 FGFR2 chr10: 123,096,374 - 123,498,771 402.4
14q22 BMP4 chr14: 54,382,690 - 54,445,053 62.4
We concluded that sequencing of all GWAS-implicated regions in a wide range of pop-
ulations, together with functional analyses, would be necessary to fully understand the role
of these genes/regions in the etiology of NSCL/P. This would give insight into shared and
population-specific signals, as well as the role of rare variants in NSCL/P.
1.4.2 Multiethnic Study of Orofacial Clefts
The multiethnic OFC GWAS (also known as the Pittsburgh OroFacial Cleft [POFC] study)
was a study conducted in several populations consisting of 11,727 participants recruited from
18 sites across 13 countries from North America, Central or South America, Asia, Europe,
and Africa. The overall study cohort includes OFC-affected probands, their unaffected fam-
ily members and controls with no known history of OFC or of other craniofacial anomalies.
Thus, there are many family structures present in the OFC study, including singleton cases
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and controls, sibling pairs, case-parent trios, and larger families. Currently, we have only an-
alyzed independent (unrelated) cases, controls and trios. We conducted standard association
in the cases and controls, TDT in the trios, and used inverse-variance weighted meta-analysis
to estimate the effect of each variant on NSCL/P. There were a total of 6,480 participants
(823 cases, 1700 controls, and 1319 case-parent trios) with European, Asian, African, and
Central and South American ancestry for the aforementioned analysis. All subjects were
genotyped on the same microarray with approximately 580,000 SNPs. Ideally, we would like
to combine all participants into the same analysis to maximize the information available, as
some signals might be lost by only examining independent trios, cases, and controls.
Again, we replicated many (but not all) previously-associated regions. Some of these
regions showed evidence of shared signal between the different subpopulations (e.g. NTN1 ),
but many regions appeared to be population specific. We would like to be able to quantify
the heterogeneity we see in these signals between populations and assess if the difference we
see is due to low power in some subpopulations with smaller sample size.
This study also collected extensive phenotypes on participants. We have detailed cleft
information (type of cleft, completeness, and side affected) for each participant with a cleft.
We believe that there are underlying genetic differences that contribute to these phenotypic
differences we see. Very little is known about the differentiation between the cleft subtypes
(isolated cleft lip, cleft lip with cleft palate, and isolated cleft palate), the side of the face
affected in unilateral cleft lips, and why OFCs are more frequent in males. There is a need
for a statistical test to find any underlying genetic components that contribute to these cleft
differences.
1.5 SUMMARY
In this integrated dissertation we examine methods applied to genetic epidemiology studies
of family-based and population-based data. This includes two main components. The first
component addresses methods for combining data from mixed structure designs. The second
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component examines methods of determining genetic sources of phenotypic heterogeneity in
orofacial clefts.
Specifically, we address two hallmarks of the study of complex disease: (1) How can
family data be combined with case-control data from the same study to improve estimates
of disease association in a way that is robust to model misspecification? and (2) How can
genetic sources of phenotypic heterogeneity be identified in case-control and family-based
studies?
In chapter 2, we provide an overview of existing methods for analyzing mixed data types.
First, methods for population-based and family-based data analysis are presented followed
by two classes of methods for combining these two data types into a single analysis. Mixed
data can be analyzed in two primary ways – via meta-analysis of the separate signals from the
two data sources and via a joint, retrospective likelihood. An analysis of the strengths and
weaknesses of these methods is given, including a practical application of one such method
to a genome-wide association study for orofacial clefting.
In chapter 3, we propose an empirical Bayes-type estimator for combining mixed data
structures in a retrospective likelihood to leverage the assumption of HWE among controls
and parents within trios to the extent that the data supports HWE.
In chapter 4, we present an overview of phenotypic heterogeneity in the study of complex
traits including methods for detecting genetic contributions to phenotypic heterogeneity.
A published study examining genetic sources of phenotypic heterogeneity in a targeted
sequencing study is given in chapter 5.
In chapter 6, we apply a method for detecting genetic differences in orofacial clefting to
a genome-wide meta-analysis. We present a novel approach to visually representing hetero-
geneity of genetic loci via the ”cleft map”.
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2.0 GENOME-WIDE ASSOCIATION STUDIES FOR MIXED DATA
STRUCTURES
2.1 INTRODUCTION
GWASs are popular tools used to detect genetic loci associated with a trait of interest.
The underlying concept for GWAS is to perform a test of association for each SNP across
the genome, and then examine the regions showing the most statistical significance. Thus,
GWAS is applicable for use with a variety of trait distributions. Virtually any statistical
model can be used to test each variant; the primary limitation is the computing power
required to fit such a model for millions of genetic markers.
With dichotomous traits, the most common method for GWAS is the case-control asso-
ciation study which uses either a simple chi-squared test or logistic regression to examine
differences in allele or genotype frequencies between cases and controls at each SNP. This
type of analysis is straightforward and easy to implement, but is subject to false positive
associations when there is population stratification; population allele frequency differences
can be confounded with disease frequency if not properly accounted for.
A family-based design with case-parent trios uses a different statistical method to exam-
ine linkage and association of a genetic marker and the trait. The most common methods for
case-parent trios include the TDT and a conditional on parental genotype (CPG) approach.
Unlike the case-control approach, family-based methods are not subject to inflation of results
due to population substructure, as examining transmission between parents and offspring
removes any potential effect caused by population allele frequency differences. However,
family-based methods have less statistical power than the population-based case-control de-
signs for the same number of individuals studied.
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More recently, methods have been developed to combine these two data structures, grant-
ing the most statistical power while still protecting against artificial inflation of results. Meth-
ods for analyzing mixed data structures leverage more information from a study with mixed
data types than examining each data type separately. This chapter provides an overview
of existing statistical methods for performing GWAS with cases and controls, case-parent
trios, and the combination of them. We employ one such method for combining case-control
and case-parent trios to explore genome-wide association in the Multiethnic OFC study.
In particular, we demonstrate how utilizing mixed data structure increases the information
obtained from a GWAS, without complicated methodology.
2.2 METHODS
This section first provides a basic overview of the statistical methods used for separate
analysis of population-based and family-based data, then gives a survey of the methodology
currently in place for combining these two data structures.
2.2.1 Case Control
The goal of a case-control study is to identify risk groups by observing outcomes; the primary
interest is estimating the genotypic relative risk (GRR) given by equation 2.2.1.
γg =
P (D = 1|G = g)
P (D = 1|G = 0) , g = 1, 2 (2.2.1)
The retrospective likelihood of the observed genotypes is composed of the independent
components for cases and controls where each component is a straightforward multinomial
probability. The likelihood for a case-control analysis is:
L(γ1, γ2, p) =
∏
j
P (Gj|Dj = 0)
∏
k
P (Gk|Dk = 1)
=
∏
j
P (Gj = g)
∏
k
γgP (Gk = g)∑
γg∗P (Gk = g∗)
(2.2.2)
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where
p = minor allele frequency, P (a), in the population
γ1 = relative risk of clefting for Aa compared to AA
γ2 = relative risk of clefting for aa compared to AA
Di = disease status of individual i
Gi = genotype of individual i
The likelihood is parametrized by the two relative risk components and the minor allele
frequency (a nuisance parameter). Typically, a genetic model is employed to reduce the
GRR parameters to one parameter. The common genetic models used to do so are given in
Table 2.1.
Table 2.1: Commonly used genetic models in terms of relative risk parameters
Genetic Model γ1 γ2
Additive γ 2γ − 1
Dominant γ γ
Recessive 1 γ
Multiplicative γ γ2
2.2.2 Trios
When studying families, it is the transmission of alleles from parent to offspring that is
analyzed. In this sense, parents are used as genotypic controls for their children. There are
three main ways in which trios are analyzed using the idea of parents as genetic controls,
each illustrated in the Figure 2.1 [74].
In the toy examples in Figure 2.1, both parents are heterozygous (Aa). (One can easily
extend this to all possible parental genotypes.) One allele from each parent is transmitted to
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(a) TDT (b) Conditional Approach (c) Combined Likelihood
L =
∏
P (Goi |Doi = 1,Gpi) L =
∏
P (Goi |Doi = 1,Gpi) L =
∏
P (Gpi , Goi |Doi = 1)
Figure 2.1: Three main ways of estimating association in trios
the child (one A from mom, one A from dad). Example A is the TDT, which is a matched
analysis comparing the child to its anti-self, the unobserved instance of a child with both non-
transmitted alleles [71]. Comparing the child with its anti-self is one way to condition on the
parental genotype. Similarly, Figure 2.1b shows the conditional logistic regression method
which compares the proband to unobserved pseudo-siblings with all possible transmission
patterns. Again, these pseudo-siblings are not observed, but the result of conditioning on
the parental genotype to create a matched analysis. If an additive genetic effect is assumed,
example 2.1a and example 2.1b are equivalent.
These first two methods only model the probability of the childs genotype conditional
on parental genotypes, but example 2.1c models the probability of the entire trios genotype.
The final method is a combined likelihood approach which jointly models the probability of
parental and case genotypes. It is notable that the likelihood for example C factors into two
components – one of which is the likelihood from example B.
Under the null hypotheses of all these methods, the alternative genotypes are equally
likely to have been transmitted to the case; any deviation from this expected distribution in
the proband is evidence of association at that locus [74].
Proceeding with the model from example C in Table 2.1, the likelihood for jointly mod-
eling proband and parent genotypes is given by [68]
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L(γ1, γ2, p) =
∏
i
P (Goi ,Gpi|Doi = 1)
=
∏
i
P (Goi ,Gpi|Di = 1)P (Gpi|Doi = 1)
=
∏
i
γgP (Goi |Gpi = gpi)P (Gpi = gpi)∑
g∗ γg∗P (Goi = g∗|Gpi = gpi)P (Gpi = gpi)
×∑
g γgP (Goi |Gpi = gpi)P (Gpi = gpi)∑
gp∗
∑
g∗ γg∗P (Goi = g∗|Gpi = gp∗)P (Gpi = gp∗)
(2.2.3)
where
p = minor allele frequency, P (a), in the population
γ1 = relative risk of clefting for Aa compared to AA
γ2 = relative risk of clefting for aa compared to AA
Doi = disease status of offspring from trio i
Goi = genotype of offspring from trio i
Gpi = (Gp1 , Gp2) = genotypes of parents from trio i
The likelihood is again just a multinomial likelihood for the proband, conditioning on the
disease status to model GRR and parental genotypes. Using Bayes theorem and the law of
total probability, this is expanded into a function of the GRR parameters and the observed
genotypes. This model assumes that both alleles are equally likely to be transmitted (i.e.
no meiotic drive) and that survival to birth does not depend on genotype.
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2.2.3 Combined Analysis
There are two main philosophies for combining cases, controls, and trios in such a way
as to model both association and transmission. The first is a meta-analysis approach, in
which separate analyses are conducted for the case-control data and the trio data, and then
estimates of disease risk are combined in standard meta-analysis methods. The final estimate
of disease risk is a weighted combination of the individual analyses disease risks.
The other approach combines all individuals in a single likelihood, and estimates one
overall disease risk. Many current methods exist for this approach, with varying assump-
tions and data type inclusions [56] [18]. These methods make a rare disease assumption,
and furthermore assume that the disease risk is the same for probands and cases, and that
all individuals are sampled from the same population. The class of likelihood-based esti-
mators are more powerful than meta-analysis-type methods under all genetic models except
dominant and whenever modeling association with rare variants [18].
2.2.3.1 Meta-Analysis Approach
Meta-analysis approaches combine distinct estimates from case-control and trio analyses.
Two specific approaches are described in this section.
The method introduced by Kazeem and Farrall combines log odds ratios from the sepa-
rate case-control and trio analyses into a weighted log odds ratio (ψ) [34].
ψ =
wcclog(ORcc) + wtdtlog(ORtdt)
wcc + wtdt
(2.2.4)
wi =
1
V ar[log(ORi)]
The corresponding test statistic is given in equation 2.2.5
Q =
ψ2
V ar[ψ]
∼ χ2 under H0 (2.2.5)
And the assessment of heterogeneity of effects is tested with equation 2.2.6.
X2H =
2∑
i=1
wi(log(ORi)− ψ)2 ∼ χ2 under H0 (2.2.6)
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Combining the effect estimates in this manner implicitly assumes that the effects are
homogeneous. In this regard the meta-analysis approach is identical to a likelihood-based
approach (discussed in the next section) which estimates only one effect, assuming that the
effects are identical between cases and trio probands.
This approach is extremely easy to implement, and provides a natural interpretation of
the combined odds ratio. Independent (i.e. unrelated) cases, controls, and trios are required.
If there is overlap between the cases, control, and trios, the preferred method is that from
Chen and Lin which uses a robust variance estimate to allow for correlated data [13].
These meta-analysis approaches are useful tools for preliminary analyses; however, they
are not the most powerful methods to detect association.
The straight-forward weighted meta-analysis approach was performed with independent
cases, controls, and case-parent trios from the OFC GWAS study. (Results are detailed in
the section Genome-wide association study with mixed data structure for results).
2.2.3.2 Likelihood-Based Approach
Contrary to the meta-analysis approach, the likelihood approach combines cases, control, and
trios into a single likelihood to obtain one estimate of disease association. The likelihood
employed is a retrospective likelihood, incorporating the disease status of individuals into
the probabilities within the likelihood. Using the retrospective likelihood not only accounts
for the fact that cases, controls, and incident probands were recruited based on their disease
status, but also establishes a framework for using genetic assumptions about the distribution
of genotype probabilities to obtain more efficient estimates of the GRR parameters. The
general form of the likelihood based approaches is given by [56] (2.2.7).
L =
I∏
i=1
P (Gpi , Gi|D0i = 1)×
J∏
j=1
P (Gj|Dj = 1)×
K∏
k=1
P (Gk|Dk = 1) (2.2.7)
This can be written in terms of the relative risk parameters and the minor allele frequency
(as in equation 2.2.2).
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L(γ1, γ2, p) =
I∏
i=1
γgP (Goi |Gpi = gpi)P (Gpi = gpi)∑
g∗ γg∗P (Goi = g∗|Gpi = gpi)P (Gpi = gpi)
(2.2.8)
×
∑
g γgP (Goi |Gpi = gpi)P (Gpi = gpi)∑
gp∗
∑
g∗ γg∗P (Goi = g∗|Gpi = gp∗)P (Gpi = gp∗)
×
J∏
j=1
P (Gj = g)
×
K∏
k=1
γgP (Gk = g)∑
g∗ γg∗P (Gk = g∗)
In order to incorporate unrelated controls and unaffected parents, we make a rare-disease
assumption (equation 2.2.9). Similarly we make a rare-disease approximation for cases such
that equation 2.2.10 holds.
P (G = g|D = 0) ≈ P (Gp,1 = g) (2.2.9)
P (G = g|D = 1) = γgP (Gp,1 = g)∑
g∗ γg∗P (Gp,1 = g∗)
≈ γgP (G = g|D = 0)∑
g∗ γg∗P (G = g∗|D = 0)
(2.2.10)
This assumption implies that the underlying genotype probabilities are the same for
the three types of data being combined, i.e. that these three samples come from the same
population. Epstein et al. provide a statistical procedure for testing this assumption in the
mixed data setting [18].
In addition to these assumptions, a further assumption of Hardy-Weinberg Equilibrium
(HWE) can be made in order to obtain efficient GRR estimates. The assumption of HWE
incorporates many assumptions including random mating, equal allele frequencies among
the sexes, no mutation, no selection, etc. The statistical consequence of assuming HWE is
that the genotype probabilities can be neatly defined in terms of the frequency of the major
allele – P (AA) = (1− p)2, P (Aa) = p(1− p), and P (aa) = p2, where p = P (A). Using the
genotype probabilities under HWE provides very efficient estimates of GRR, however, any
deviation in genotypic frequencies away from HWE can cause extreme type-1 error inflation.
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In order to avoid this, one possibility is to filter out variants that deviate from HWE
prior to running an association test. This will theoretically improve the robustness of the
procedure, but will also lead to a type-1 error inflation if the multiple tests in this two-stage
procedure are not accounted for.
Another option is to forgo the assumption of HWE in the genotypic probabilities and
instead model the mating type frequencies of the parents. The six possible mating-type
frequencies and their corresponding frequencies, using parental mating-type estimation and
under HWE, are shown in Table 2.2 [18].
Table 2.2: Genotype Frequencies
Gp Go under HWE not under HWE
AA,AA AA (1− p)4 µ6
AA,Aa AA p(1− p)3 1
2
µ5
AA,Aa Aa p(1− p)3 1
2
µ5
Aa,Aa AA p2(1− p)2 1
4
µ4
AA,Aa Aa p2(1− p)2 1
2
µ4
AA,Aa aa p2(1− p)2 1
4
µ4
AA,aa Aa 2p2(1− p)2 µ3
Aa,aa Aa p3(1− p) 1
2
µ2
Aa,aa aa p3(1− p) 1
2
µ2
aa,aa aa p4 µ1
Estimating the mating-type frequencies instead of assuming HWE provides a robust
estimate of the GRR, even when HWE does not hold. However, if HWE does hold, this
method loses efficiency compared to the one in which HWE is assumed.
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2.3 GENOME-WIDE ASSOCIATION STUDY WITH MIXED DATA
STRUCTURE
We performed the genome-wide association scan of NSCL/P for the OFC study using two
subsets of our multiethnic sample and the meta-analysis approach from Kazeem and Farrall.
We partitioned the total sample into two mutually exclusive analysis sets for the current
study: (1) a subset of 1,319 case-parent trios (i.e. 3,957 individuals; note, from each multiplex
family only one trio was chosen), and (2) a subset of 823 unrelated CL/P cases and 1,700
unrelated controls. There was no overlap between the case-parent trio group and the case-
control group; the groups were considered to be independent, were analyzed separately, and
then the effects were combined via meta-analysis.
The effect of each genetic variant (293,633 genotyped SNPs with MAF>1%) was analyzed
within the separate groups first, then combined into a weighted effect estimate. Cases and
controls were analyzed using logistic regression (including principal components of ancestry
as covariates to adjust for population substructure) . The case-parent trios were analyzed
with the TDT. The log odds ratios from the separate analyses were combined using inverse-
variance weighting. The resulting log odds ratio was compared to a chi-square distribution
with one degree of freedom, as prescribed by the Kazeem and Farrall method. We also
examined the heterogeneity of the effects, and excluded the variants for which the effects
were driven by one group only.
In order to detect signals common to all ancestry groups, the first scan included individ-
uals from all populations. Then, in order to detect population-specific signals, association
scans within each ancestral group (European, Asian, and Central/South American as defined
by principal components of ancestry) were performed. (Stratified analysis was not performed
separately in the African group due to small sample size.) The same procedure (i.e., meta-
analysis of results from the trio and case-control subsets) was used for the multiethnic and
population-specific scans.
Using the results from combining effects from separate case-control and TDT scans, we
identified more loci than with either scan alone (Figure 2.2 & Figure 2.3 - for full results,
please see the published paper [41]).
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In the meta-analysis with all populations, several known NSCL/P loci reached genome-
wide significance (PAX7, ARHGAP29, IRF6, 8q24, and NTN1, Figure 2.2). Only two of
these regions (IRF6 and 8q24) demonstrated genome-wide significant associations when ex-
amining the results from the separate TDT and case-control analyses.
Figure 2.2: Results of the multiethnic GWAS for (A) meta-analysis, (B) TDT, (C) case-
control
Furthermore, among individuals with European ancestry, we identified two genome-wide
significant associations on 8q24 (a known NSCL/P locus) and 17q23a (a novel association).
Three loci approached genome-wide significance: 1p36 (PAX7 ), 17p13.1 (NTN1 ), and a
novel locus on 6p21.
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Figure 2.3: Results of the European GWAS for (A) meta-analysis, (B) TDT, (C) case-control
These association signals are summarized in Table 2.3. Regional association plots for
these five significant/suggestive peaks are shown in Appendix C.
Table 2.3: Significant and suggestive loci from European GWAS
Locus SNP Risk Allele TDT OR CC OR META OR 95% CI P-value
1p36.13 rs9439714 C 1.62 1.38 1.52 1.30-1.89 1.91× 10−7
6p21.33 rs79411602 C 1.67 1.31 1.52 1.29-1.78 2.92× 10−7
8q24 rs72728734 G 2.22 1.84 2.04 1.70-2.44 7.33× 10−15
17p13.1 rs7406226 A 1.50 1.73 1.59 1.33-1.89 2.16× 10−7
17q23.2 rs1588366 A 1.63 2.09 1.78 1.46-2.17 1.41× 10−8
Analyzing the mixed data types of the OFC study yielded many genome-wide association
including both known CL/P risk loci and novel loci. As demonstrated by the manhattan plots
for the meta-analysis, TDT, and case-control results, the meta-analysis approach combined
information from both scans resulting in strong signals where both groups demonstrated some
evidence of association. The resulting effect estimates provided a natural interpretation of
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the results and any heterogeneity in effects between the trio and case-control groups was
detected by examining the separate effect estimates.
The OFC study utilized the meta-analysis approach because of the ease of implementa-
tion and to protect against type-1 error inflation that can arise when the strict assumptions
of the likelihood-based methods are violated. Although the meta-analysis approach has re-
duced power compared to the likelihood-based approach, we still detected novel CL/P risk
loci.
2.4 DISCUSSION
There are two broad categories of methods that incorporate data from population-based
and family-based designs. The first, the meta-analysis approach, separately analyzes the
information from different data structures and then uses inverse-variance-weighted meta-
analysis techniques to combine those estimates. This method is easy to implement and
does not require strict assumptions about the distribution of genotype probabilities. On
the other hand, the likelihood-based methods require more strict assumptions about these
distributions of genotype probabilities. Assuming HWE in the likelihood-based estimation
techniques produces more efficient estimates of GRR than the meta-analysis approaches,
but is subject to a rather dramatic increase in type-1 error. When these assumptions are
violated, the estimates are inappropriately inflated. Removing this assumption of HWE in
the likelihood-based methods offers one solution for balancing the trade-off between efficiency
and bias.
In the example of NSCL/P, the robustness of meta-analysis approach was preferred (as
demonstrated in the Multiethnic OFC GWAS) and still lead to the discovery of novel genetic
loci for NSCL/P. However, if the assumptions of the likelihood-based methods could be
relaxed and/or the estimates made more robust to violation of assumptions, then likelihood-
based methods could be extremely useful in discovering new loci. Such methods may help
elucidate the genetic architecture of clefting and other complex traits.
24
The methods for combining data from population-based and family-based studies dis-
cussed in this chapter are those for which transmission is directly modeled. It is worthwhile
to note that many methods exist to adjust for the inclusion of related individuals, usually
via a mixed model accounting for pairwise kinship of participants, but these methods do
not model transmission of alleles from parent to offspring. An overview of these methods
is given in [19]. Many of these methods, including one popular choice (EMMAX, [33]), are
developed for quantitative phenotypes, although recently, methods have been adapted to
incorporate binary traits [12]. While these methods provide useful models to account for
population stratification and relatedness (including cryptic relatedness) among individuals,
this dissertation is focused on methods which model transmission.
25
3.0 EMPIRICAL BAYES-TYPE ESTIMATION METHOD FOR MIXED
DATA STRUCTURES
3.1 INTRODUCTION
A characteristic feature of GWAS is the selection of potential genetic loci to further exam-
ine after the preliminary association scan. These loci are typically selected using a p-value
threshold for the association test. Choices for this threshold are determined by sample size
and whether the scan is hypothesis-generating or confirmatory in nature; common thresholds
are 5.00× 10−5 and 5.00× 10−8. A narrow window based on genomic position, linkage dis-
equilibrium with the most-significant SNP, and topological domains is also frequently used
to select SNPs for follow-up. Lack of statistical significance beyond such thresholds in this
preliminary step may exclude a positively-associated SNP from any downstream analyses.
This type 2 error is particularly detrimental in hypothesis-generating scans for association
as any downstream analyses, including replication efforts, will not evaluate association or
biologic importance without the preliminary nomination of the variant. However, this does
not grant license for high type-1 error levels. Thus, powerful methods for detecting associa-
tions that control the type-1 error rate, are necessary in order to produce potential genetic
loci associated with complex traits.
Moreover, these powerful methods are needed in the mixed data structure setting. As
described in chapter 2, retrospective likelihoods provide an intuitive likelihood specification
for retrospective sampling including mixed data types and a framework for utilizing con-
straints to increase statistical power. However, existing methods for combining case-parent
trios with unrelated cases and controls in a retrospective likelihood approach either assume
HWE – which is efficient but biased when the data does not follow HWE – or remove any
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assumption of genotype distribution – which is less efficient. The first of these methods,
proposed by Nagelkerke et al. [56], made use of the HWE constraint in a retrospective likeli-
hood combining independent cases, controls, and case-parent trios. The second method, set
forth by Epstein et al. [18], removed the assumption of HWE from the estimation of GRR
in a retrospective likelihood combining independent cases, controls, and case-parent trios.
Without knowing the true deviation from HWE for each genetic variant, the most powerful
statistical model cannot be selected apriori.
An ideal estimator would be a combination of these two methods such that it utilized
a HWE equilibrium assumption to shrink estimates but only to the extent that the data
supported the HWE assumption. The estimate would not be prone to the bias and corre-
sponding type-1 error inflation from a constraint of HWE but would not lose efficiency in
estimating the GRR by estimating many nuisance parameters. We propose such an esti-
mator – an empirical Bayes-type shrinkage estimator – which combines the constrained and
unconstrained estimation approaches previously described.
The proposed estimator maximizes statistical power and avoids increased type-1 error
through the use of a data-adaptive method leveraging the HWE assumption. It achieves this
by estimating the GRR parameter via ”shrinkage” of the model-free estimator (not assuming
HWE) towards a model-based estimator (assuming HWE). The procedure described here was
introduced by Mukherjee and Chaterjee and applied to retrospective case-control studies
by Luo et al. [54] [48]. We extend this method to estimate genetic risk incorporating
case-parent trios simultaneously with independent cases and controls. A key feature of
the proposed estimator is that it relaxes the model constraints through a completely data-
adaptive shrinkage estimation approach, which controls the number of false positives due to
departure from HWE.
We evaluate the performance of the proposed method compared with a constrained and
unconstrained method using both simulated genetic data and real data from the Multiethnic
OFC study. In particular, the application of this method to the Multiethnic OFC study
provides insight into the performance of the proposed estimator on a genome-wide scale.
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3.2 METHODS
3.2.1 Assumptions and Notation
We will assume a sample a cases, controls, and case-parent trios that are all genotyped at
a SNP. For generalization, we denote the two alleles at the SNP A and a. G represents the
observed genotype of the unrelated individuals (i.e. cases and controls), Go the observed
genotype of the affected offspring of the trio, and Gp = (Gp1, Gp2) the unordered genotypes
of the parents of the trio. Each genotype, g, is coded as the number of copies of the minor
allele, a, taking values 0, 1, and 2. We will further assume no Mendelian errors in the trios
and that no parent within a trio is affected. We denote affection with D, equaling 1 for
affected and 0 for unaffected individuals. We will again use a rare-disease approximation as
in equation 2.2.9 to model genotype probabilities.
3.2.2 Likelihood Formation
Consider again the the retrospective likelihood for combining independent cases, control,
and case-parent trios (2.2.7).
This likelihood depends on the GRR, γ, and the genotype probabilities from controls
and trio parents. We use a reparameterization to define the genotype frequencies (p0, p1,
and p2) in terms of HWE parameters θ and ω (3.2.1) [45].
θ =
1
2
log(
4p0p2
p21
)
ω =
1
2
log(
p0
p2
) (3.2.1)
This defines the genotype probabilities of controls in terms of their HWE parameters θ
and ω (3.2.2).
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p00 = P (AA) =
e2ω
1 + e2ω + 2eω−θ
p01 = P (Aa) =
2eω−θ
1 + e2ω + 2eω−θ
(3.2.2)
p02 = P (aa) =
1
1 + e2ω + 2eω−θ
The deviation from HWE is measured with the parameter θ. Values close to zero indicate
mild to no deviation from HWE, whereas larger absolute values indicate violation of the
HWE assumption. Specifically, θ > 0 corresponds to excess homozygosity whereas θ < 0
corresponds to excess heterozygosity.
We use the genotype frequencies from parents of case probands and unrelated controls
to estimate the HWE parameters in two ways – unconstrained (3.2.3) and constrained under
HWE (3.2.4).
ωˆ =
1
2
log(
n0
n2
)
θˆ =
1
2
log(
4n0n2
n21
) (3.2.3)
ω˜ = log(
2n0 + n1
n1 + 2n2
)
θ˜ = 0 (3.2.4)
Given θ and ω, we characterize the genotype frequency of cases and trios in terms of
genotype frequencies of controls and parents (Table 3.1, Table 3.2, and Table 3.3).
Thus, the likelihood for jointly modeling the GRR for cases, controls, and case-parent
trios L = L(β, θ, ω) is a function of the relative risk and HWE parameters, where β is the
log(GRR).
To model GRR parameters, we could consider an unstructured model that allows for
estimation of γ1 and γ2 without the assumption of a genetic model. However, assuming an
additive genetic model reduces the number of parameters to estimate and eases computation.
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Table 3.1: Genotype frequencies of controls.
genotype count P (Gctrl|D = 0)
0 N00 p00
1 N01 p01
2 N02 p02
Table 3.2: Genotype frequencies of cases.
genotype count P (Gcase|D = 1)
0 N10
p00
p00+γ1p01+γ2p02
1 N11
p01
p00+γ1p01+γ2p02
2 N12
p02
p00+γ1p01+γ2p02
The additive model (i.e. γ1 = γ, γ1 = 2γ−1) is assumed here to reduce labor of computation
and because of its widespread use in association studies of orofacial clefting, our primary
application of this method.
Let βˆ(θ) denote the maximum likelihood estimate of β for a fixed θ, and βˆ0(θ = 0)
denote the maximum likelihood estimate of β subject to the constraint that θ = 0 (i.e.
HWE holds for controls and parents). Both of these estimates can be obtained through
standard maximum likelihood procedures, although it is worth noting that the estimates are
obtained through iteratively through numerical optimization techniques as the formula for
the MLEs cannot be expressed in closed form.
3.2.3 Construction of the Empirical Bayes-Type Estimator
We propose to combine βˆ and βˆ0, the constrained and unconstrained estimators, using an
empirical Bayes-type shrinkage estimation approach as in [54].
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Table 3.3: Genotype frequencies of trios.
parental genotype offspring genotype count P (Gparents, Goffspring|Doffspring = 0)
0,0 0 N000 p
2
00/R
0,1 0 N010 p00p01/2R
0,1 1 N011 γ1p00p01/2R
1,1 0 N110 p
2
01/4R
1,1 1 N111 γ1p
2
01/2R
1,1 2 N112 γ2p
2
01/4R
0,2 1 N021 γ1p00p02/R
1,2 1 N121 γ1p01p02/2R
1,2 2 N122 γ1p01p02/2R
2,2 2 N222 γ2p
2
02/R
R = p200 +
1
2
p00p01 +
1
4
p201 + γ1(
1
2
p00p01 +
1
2
p201 + p00p02 +
1
2
p01p02) + γ2(
1
4
p201 +
1
2
p01p02 + p
2
02)
In order to construct the empirical Bayes-type estimator we assume an underlying distri-
bution for a hyperparameter, called θ, with expectation zero and some variance, τ 2. Thus,
the conditional distribution of θˆ|θ has the same distribution as θ, with mean θ and variance
σ2θ . By the rules of conditional expectation and variance, θˆ|θ has mean zero and variance
τ 2 + σ2θ .
Importantly, only the hyperparameter is assumed to have an underlying distribution,
and other parameters are estimated with standard maximum likelihood methods, granting
the name Bayes-type estimation. The general formulation of a Bayes-type estimator is a
weighted average of a constrained estimate, βˆ0, and an unconstrained estimate, βˆ (3.2.5).
βˆEB =
(
σˆ2θ
τˆ 2 + σˆ2θ
)
βˆ0 +
(
τˆ 2
τˆ 2 + σˆ2θ
)
βˆ (3.2.5)
Considering a general empirical Bayes-type estimator as some function φ = f(θ), where
θ is the nuisance parameter (here, the HWE parameter) is assumed to have a Normal dis-
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tribution with some specific variance-covariance matrix, A. Applying Taylor’s expansion of
ψ about θ = 0, the prior on ψ can be approximated with a Normal distribution with mean
f(0) and variance-covariance matrix Vφ = f
′(0)TAf ′(0) [54]. Then the formulation of the
empirical Bayes-type estimator φ is given in 3.2.6.
φˆ = f ′(0)TAf ′(0)[Vˆφ + f ′(0)TAf ′(0)]−1f(θˆ) + Vˆφ[Vˆφ + f ′(0)TAf ′(0)]−1f(0) (3.2.6)
Thus, using 3.2.6, the formulation of the empirical Bayes-type estimator for combining
the constrained GRR estimate [under HWE, βˆ0(θ = 0)], with the unconstrained GRR esti-
mate [βˆ(θˆ)] is given in equation 3.2.7. Mukherjee and Chatterjee provide a detailed rationale
and general formulation for empirical Bayes-types estimators [54].
βˆEB = βˆ − Vˆβˆ(Vˆβˆ + θˆ2∆ˆT ∆ˆ)−1(βˆ − βˆ0) (3.2.7)
where Vˆβˆ is the estimated variance-covariance matrix of βˆ and ∆ˆ =
δβˆ(θ)
δθ
|θ=0.
This proposed estimate is a weighted combination of the constrained and unconstrained
estimates. This new estimate should have the ideal properties of being closer to the con-
strained estimate when HWE is indeed true in the population, and closer to the unconstrained
estimate otherwise.
Intuitively the gradient function, ∆ˆ, represents rate of change of the unconstrained es-
timator in direction of θ at the point when the genotype frequencies are under HWE. The
influence that θˆ has in the weighting of the empirical Bayes-type estimator depends on ∆ˆ,
such that more severe deviation from HWE weights the estimator more heavily towards
the unconstrained estimate and vice versa. We employ a first-order Taylor expansion to
approximate the ∆ˆ (3.2.8).
∆ˆ ≈ 1
θˆ
(
βˆ − βˆ0
)
(3.2.8)
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In order to obtain the asymptotic properties of βˆEB, we note that the score function,
that is the derivative of the log-likelihood with respect to the GRR, can be expressed as in
equation 3.2.9.
∑
i  cases, probands
[(
xiN1i
p1i
)(
δp1i
δβ
)
+
(
(1− xi)Npi1,pi2,i
ppi1,pi2,i
)(
δpgi1,gi2,i
δβ
)]
= 0 (3.2.9)
where xi = I(i  cases)
1− xi = I(i  probands)
N1i = number of cases of genotype i
Npi1,pi2,i = number of trios with parent genotypes pi1 and pi2, and proband genotype i
Consequently, we can construct a partial M-estimator of the form
∑
ψ = 0 using equa-
tion 3.2.9 and creating an extension for the empirical Bayes-type estimator (3.2.10). In this
formulation, we are ignoring variation in Vˆβˆ and ∆ˆ and treating them as known. Logically,
the variance of these quantities approaches zero as the sample size increases, so this assump-
tion that they are fixed is only inappropriate in small sample sizes, which is uncommon for
genome-wide association studies in general.
∑
i  cases, probands

(
xiN1i
p˜1i(β0)
)(
δp˜1i(β
0)
δβ0
)
+
(
(1−xi)Npi1,pi2,i
p˜gi1,gi2,i(β0)
)(
δp˜gi1,gi2,i(β
0)
δβ0
)
(
xiN1i
p1i(β)
)(
δp1i(β)
δβ
)
+
(
(1−xi)Npi1,pi2,i
pgi1,gi2,i(β)
)(
δpgi1,gi2,i(β)
δβ
)
β − Vˆβˆ(Vˆβˆ + θˆ2∆ˆT ∆ˆ)−1(β − β0)− βEB
 = 0 (3.2.10)
where p˜(β0) = the genotype frequency under the constrained model
p˜(β) = the genotype frequency under the unconstrained model
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Thus, a straightforward application of M-estimation theory provides that equation 3.2.11
holds [72].
√
N(βˆEB − βEB) o∼ N(0, VN(βEB)) (3.2.11)
Using this theory we can construct a robust sandwich estimate of the variance through
equation 3.2.12.
VN(βEB) = A
−1
N BN [A
−1
N ]
T (3.2.12)
where AN =
1
N
N∑
1
−ψ′
BN =
1
N
N∑
1
ψψT
The construction of asymptotic variance-covariance matrix is given in Appendix B.
We can then construct a simple Wald-type test using the resulting estimate of βˆEB and
Vˆ (βˆEB) via equation 3.2.13 to test the null hypothesis of no association, H0 : βEB = 0.
Given the theory from M-estimation, this test statistic follows a χ2 distribution with one
degree of freedom.
Q =
βˆ2EB
Vˆ (βˆEB)2
(3.2.13)
3.3 RESULTS
3.3.1 Simulation Study
We perform simulations of the empirical Bayes-type estimator, compared to the constrained
and unconstrained estimators, using the robust variance estimates from the M-estimation
framework. Under the null hypothesis (i.e. γ = 0), we simulated 10,000 genetic variants
for equal sample sizes (Ncases = 500, Ncontrols = 500, Ntrios = 500), varying θ (θ = 0,
0.5log(1.2), 0.5log(1.6), and 0.5log(2.0) representing no, small, modest, and large deviations
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from HWE) and minor allele frequency (MAF = 0.1, 0.2, 0.3). For each of these settings,
the robust constrained, unconstrained, and empirical Bayes-type estimators are extremely
conservative (average results shown in Table 3.4). Under an alternative hypothesis of modest
genetic association (i.e. γ = 1.5), we simulated the same sample size, HWE parameter, and
minor allele frequency settings, and observed the same extreme conservativeness in test of
all three robust estimators (Table 3.5). In each simulation, under the null and alternative
hypotheses, the empirical Bayes-type estimates of the GRR behave as one would expect:
they are equivalent to the constrained estimate of GRR when θ = 0 and move closer to the
unconstrained estimate as θ increases. However, for large numbers of genetic variants and/or
large sample sizes, the computational time for calculating the robust variance estimates for
the constrained, unconstrained, and empirical Bayes-type estimators was markedly increased
compared to standard genome-wide methods.
Table 3.4: Average simulation results under null hypothesis, γ = 0.
θ MAF βˆ0 Vˆ (βˆ0) βˆ Vˆ (βˆ) βˆEB Vˆ (βˆEB)
0 0.1 0.2379 80.9960 0.2378 81.0672 0.2379 81.0671
0 0.2 0.1893 20.9505 0.1892 20.9582 0.1892 20.9573
0 0.3 0.1460 10.1467 0.1458 10.1466 0.1460 10.1468
0.5log(1.2) 0.1 0.2360 80.8334 0.2367 81.6750 0.2360 81.6679
0.5log(1.2) 0.2 0.1879 20.8835 0.1903 21.2062 0.1879 21.1972
0.5log(1.2) 0.3 0.1454 10.1245 0.1498 10.2917 0.1454 10.2835
0.5log(1.6) 0.1 0.2356 80.7066 0.2377 83.0826 0.2356 83.0619
0.5log(1.6) 0.2 0.1855 20.6941 0.1922 21.6117 0.1855 21.5865
0.5log(1.6) 0.3 0.1420 9.9943 0.1537 10.4574 0.1420 10.4351
0.5log(2.0) 0.1 0.2331 80.2845 0.2364 84.1715 0.2331 84.1381
0.5log(2.0) 0.2 0.1838 20.6200 0.1940 22.0719 0.1838 22.0317
0.5log(2.0) 0.3 0.1405 9.9439 0.1581 10.6808 0.1405 10.6461
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Table 3.5: Average simulation results under alternative hypothesis, γ = 1.5.
θ MAF βˆ0 Vˆ (βˆ0) βˆ Vˆ (βˆ) βˆEB Vˆ (βˆEB)
0 0.1 0.5438 208.9158 0.5438 209.2517 0.5438 209.2515
0 0.2 0.4964 61.1924 0.4963 61.2595 0.4963 61.2572
0 0.3 0.4529 33.3825 0.4526 33.3816 0.4529 33.3823
0.5log(1.2) 0.1 0.5410 208.7897 0.5417 212.3202 0.5410 212.3079
0.5log(1.2) 0.2 0.4946 60.0873 0.4971 61.6559 0.4945 61.6400
0.5log(1.2) 0.3 0.4514 33.0785 0.4560 34.1232 0.4514 34.1002
0.5log(1.6) 0.1 0.5412 207.1902 0.5432 217.0578 0.5412 217.0224
0.5log(1.6) 0.2 0.4912 59.2110 0.4982 63.8355 0.4912 63.7881
0.5log(1.6) 0.3 0.4463 31.9479 0.4589 34.8002 0.4463 34.7376
0.5log(2.0) 0.1 0.5371 205.0775 0.5405 221.7345 0.5371 221.6768
0.5log(2.0) 0.2 0.4885 58.1676 0.4993 65.2815 0.4885 65.1995
0.5log(2.0) 0.3 0.4437 31.4537 0.4626 36.0093 0.4437 35.9122
3.3.2 Application to Genome-wide Study of Orofacial Clefts
We applied this method to a sample of 170 cases, 835 controls, and 1050 individuals from case-
parent trios (i.e. 350 trios) of European decent (as identified through principal components
of ancestry) from the Multiethnic OFC study. Association at each of 258,543 genotyped
SNPs with MAF > 5% was examined using three methods: (1) the constrained estimation
approach using the robust sandwich variance estimate, (2) the unconstrained estimation
approach using the robust sandwich variance estimate, and (3) the empirical Bayes-type
estimation approach using the robust sandwich variance estimate.
None of these methods demonstrates any statistical significance (i.e. p > 0.05 for all vari-
ants). However, if the ranked order of the variants is considered rather than a p-value thresh-
old, the highest ranked variants are those from the regions which demonstrated genome-wide
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statistical significance (i.e. 8q24 and 17p13.1) in the preliminary association scan in chapter 2
as shown in Table 3.6.
Table 3.6: Top 20 variants from empirical Bayes-type estimation.
Ranking SNP CHR BP P-value (European OFC meta-analysis)
1 rs7018093 8 129891232 1.40× 10−6
2 rs1850889 8 129890405 1.45× 10−6
3 rs7841974 8 129888565 1.86× 10−6
4 rs2056314 8 129875260 2.00× 10−6
5 rs7010446 8 129874453 2.06× 10−6
6 rs756122 8 129912740 2.64× 10−6
7 rs2395865 8 129903689 3.88× 10−6
8 rs10100830 8 129893934 2.98× 10−6
9 rs2119756 8 129898369 4.54× 10−6
10 rs1519851 8 129895819 4.66× 10−6
11 rs2395864 8 129903563 4.91× 10−6
12 rs4733659 8 129910410 6.06× 10−6
13 rs4733532 8 129881299 5.14× 10−6
14 rs1519849 8 129896967 9.51× 10−6
15 rs9297779 8 129986237 4.02× 10−5
16 rs7844704 8 129845635 1.64× 10−5
17 rs1519850 8 129896821 4.87× 10−5
18 rs3760257 17 61496471 9.25× 10−6
19 rs6470670 8 129913448 5.89× 10−5
20 rs873761 8 129863533 3.95× 10−5
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3.4 DISCUSSION
We constructed an empirical Bayes-type estimator as a weighted combination of a constrained
estimate (under HWE) and unconstrained estimate. The resulting estimate cannot be solved
exactly and linear approximations must be employed. In order to obtain the distribution
of the resulting estimate, a partial M-estimator was constructed and the robust sandwich
variance estimate calculated.
Because of the need for robust variance estimates of the empirical Bayes-type estimator,
the efficiency gained by employing a shrinkage-estimate is lost. This is seen in the all
three estimators – constrained, unconstrained, and empirical Bayes-type – using the robust
variance estimates. Each method is extremely conservative, and only provides a ranked order
of the variants.
These results are contrary to the presentation of empirical Bayes-type estimators to
improve efficiency [54] [48]. We believe this is largely due to the robust variance estimate,
which is indeed robust against model misspecification, but may not be useful in the context of
genome-wide analyses due to the inefficiency of the estimates and the computational burden.
Furthermore, the decrease in efficiency may also be due to the multiple approximations that
are required to formulate the empirical Bayes-type estimator (e.g. the approximation of ∆ˆ)
3.2.8. While these approximations behave well in neighborhoods of the point of expansion,
they may not achieve the same properties when used to construct an estimator which will
be tested in a genome-wide setting.
Despite these concerns of efficiency, the application to the Multiethnic OFC GWAS
demonstrates that the statistical ranking of the variants was preserved in general. Thus,
the estimator is in fact testing for genetic association and does identify regions with strong,
known effects, albeit with much less efficiency than estimators with non-robust variance
estimates.
An additional possibility for testing association with an empirical Bayes-type estimation
procedure without the robust variance estimate from M-estimation framework, would be
to perform permutations at each variant, comparing the estimate to it’s empirical distribu-
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tion. While this would provide a smaller variance estimate, it would further increase the
computational burden.
Given these considerations, other existing methods may be more useful to analyze
genome-wide associations from mixed data types. As demonstrated in chapter 2, the meta-
analysis approach combining effect estimates from logistic regression and TDT is easy to
implement and useful. If a retrospective likelihood is desired to combine cases, controls,
and trios, the SCOUT software which implements the likelihood-based method without the
assumption of HWE is preferred over methods assuming HWE [18].
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4.0 GENETICS OF PHENOTYPIC HETEROGENEITY
In the study of genetic association, a distinction is made between simple and complex traits.
Simple traits are those more-or-less following a Mendelian inheritance pattern, and are usu-
ally controlled by a single genetic factor with strong effect. Conversely, complex traits often
exhibit a sporadic inheritance pattern and often involve many genetic and environmental
factors of more modest effect sizes. Common traits are usually thought to have complex
etiology with many genes affecting the trait. Identifying these genetic variants associated
with common traits depends on the statistical power to detect them in association studies.
While variants showing strong genetic effects are easily detected, it requires large sample
sizes to detect modest effects. Furthermore, higher-frequency variants have increased power
of detection than lower-frequency variants with the same effect size. Thus, preliminary stud-
ies of complex traits mostly identified associations with common variants [84]. This leads
to the common disease-common variant (CDCV) hypothesis that has been widely used to
study complex traits. The hypothesis specifies that even though common diseases/traits are
usually determined by many genetic loci, most of the genetic risk is attributable to com-
mon variants, and each genetic locus typically has one common variant [84]. This implies
that common genetic variants, which are more readily detectable than rare variants, are
largely responsible for variation in complex diseases and traits. However, common variants
have increased statistical power for detecting associations; the contributions of rare variants
to common, complex disease may just be understudied and underpowered. While many
common-variant associations for complex traits have been detected, common variation still
has not accounted for all of the heritability present in many complex traits. The CDCV
hypothesis may not be capturing the underlying genetic etiology of complex traits, which
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could involve rare variant contribution. Further discussion of the CDCV hypothesis is given
by Pritchard and Cox [59].
Beyond the frequency of variants associated with complex traits, the heterogeneity of the
trait itself may influence the ability to identify genetic associations. The genetic architecture
of complex traits can involve numerous genetic loci (with rare or common variants) affecting
many biologic processes. Typically, complex traits exhibit more heterogeneous phenotypes
which can introduce noise into association analyses if the phenotypic variation is not entirely
related to genetic variation. Ideally, more homogeneous groups (based on genetic etiology)
would be constructed to study only the phenotypic variability associated with genetic vari-
ability. However, these groups are nearly impossible to construct without a priori knowledge
of the causal genetic mechanisms.
Statistically, the problem of phenotypic heterogeneity has been addressed in numerous
ways using classic statistical models. However, these methods have not been traditionally
employed to discover genetic differences in subphenotypes. In the following chapter, an
overview of the statistical methods capable of addressing phenotypic heterogeneity is given,
along with a comparison of how these methods operate to detect genetic sources of phenotypic
heterogeneity.
4.1 INTRODUCTION
A hallmark of common, complex disease is phenotypic heterogeneity, which arises when one
disease or disorder presents itself in multiple different ways. These differences can be based
on a number of factors including severity of disease, age of onset, and presence of disease
subtypes. The sources of this variability in phenotype are often unknown: they may be due
to genetic, environmental, or unknown variation. For complex diseases with known genetic
factors, it is very plausible that genetics also play a role in phenotypic variability.
To investigate this phenotypic heterogeneity, subphenotype groups are often defined.
These groups can be defined by categorizing a disease by severity, serological thresholds,
or even more overt subtypes that exist. Categorizing a phenotype into subphenotypes and
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studying the genetic underpinnings of each subgroup will provide meaningful insight into
the genetic architecture of a complex trait. This is especially the case when subphenotypes
have distinct causal mechanisms – only through comparing the subphenotypes would these
mechanisms be discovered. The study of subphenotypes will help elucidate the biologic
mechanisms operating to influence the trait. For example, nonsyndromic cleft lip with or
without cleft palate is a highly heterogeneous trait. It is hypothesized that some types of
clefts may share genetic etiology while others may have unique causes. Additionally, it may
be the accumulation of genetic risk factors that cause a cleft or are responsible for cleft type
differentiation. The biologic model that these risk factors operate within cannot be identified
without first understanding genetic sources of phenotypic heterogeneity.
Subgroup analysis essentially tests for three possible genetic sources of phenotypic vari-
ation, described in Figure 4.1. The first, referred to as shared genetic variants, affects
subphenotypes in the same manner, i.e. when they share a genetic etiology. The second,
referred to as subtype-specific genetic variants, increases disease risk or susceptibility in one
specific subphenotype group while the other caries the same baseline risk as controls. The
last possibility considered, referred to as modifier genetic variants, confers significantly dif-
ferent risk between subphenotypes. Modifiers can work in one of two primary ways: (1)
increasing disease susceptibility overall, but with stronger effect in one subgroup - referred
to as ”gradient”; or (2) not changing disease susceptibility overtly, but increasing risk in one
subtype while decreasing risk for another - referred to as ”opposite”.
Shared (A) Subtype-Specific (B) Modifier (C) 
Figure 4.1: Allele frequencies for possible genetic sources of phenotypic heterogeneity: (A)
Shared, (B) Subtype-Specific, and (C) Modifier.
42
Importantly, each of these models are for one genetic locus at a time. Thus, a disease
may have multiple associated loci working in concert to affect phenotypic variation through
individual contributions to overt disease risk, subtype-specific risk, and/or subphenotype
differences. Detecting these different types of heterogeneity necessitates multiple methods,
as many methods are only powered to detect one type of heterogeneity.
4.2 METHODS
There are numerous methods to examine the genetic sources of phenotypic heterogeneity
and each method addresses a very specific hypothesis and study design. Some methods
require a case-control study design while a few other lend themselves to family-based or
mixed study designs. Furthermore, many methods require genotype-level data – extracting
inference from association methods – while others used summary statistics post hoc. In
general, there is a lack of consensus for the appropriate method to use given a hypothesis
of phenotypic heterogeneity. Each hypothesis for phenotypic heterogeneity (see Figure 4.1)
requires a unique contrast to test for that type of genetic variation. The following section
addresses this gap in knowledge by comparing the existing methods for testing phenotypic
heterogeneity and the corresponding philosophical question they address.
4.2.1 Genotype-level Tests
The primary types of methods considered here are (1) a pooled approach which combines
subphenotypes for analysis, (2) a separate approach which analyzes subphenotypes inde-
pendently, (3) a case-only approach which directly compares one subtype to another, (4)
a likelihood approach for genome-wide scans of multiple types of heterogeneity, and (5) a
gene-by-environment framework that leverages information from case-parent trio designs.
Each of these methods requires genotype-level data.
43
4.2.1.1 Pooled Method
Combining subphenotypes into a broader phenotypic definition is a common approach to
increase statistical power to detect association. However, it is not a method for exploring
phenotypic heterogeneity; rather, it models perfect homogeneity of effects. Nevertheless,
employing the pooled method is useful in examining genotype-phenotype association. The
association signal detected with the pooled method may be caused by a shared variant signal,
by a subtype-specific signal, or by a type 1 modifier signal (increasing risk overall but with
different risk conferred between subphenotypes).
When it is hypothesized that subtypes share genetic etiology, combining similar pheno-
types for analysis is common. If subphenotypes have the same genetic underpinnings, then
pooling these cases yields the most power to detect genetic variation that is associated with
this pooled phenotype. If the true genetic signal is subtype-specific, it may be possible to
detect the signal in a pooled analysis but the effect will be watered down by the presence of
the unassociated second subphenotype. Finally, a modifier genetic effect could be detected
if the variant conferred at least some disease risk to each subphenotype, but the disease risk
is assumed to be identical between subphenotypes and is thus biased. If the modifier results
in effects with opposite direction, this method will fail to detect any association.
As previously mentioned, this type of analysis is commonly used for complex traits due
to limited sample sizes when phenotypes are broken down into more homogeneous groups.
While association signals using a pooled approach can be driven by a shared genetic etiology,
it is not reasonable to assume this is true without follow-up. This is particularly problematic
when one subphenotype occurs more frequently than another. As a result of disparate sample
sizes, little information is obtained from the less-frequent subphenotype and results are driven
by the more frequent one. In any case, further steps should be taken to narrow down the
source of the effect – whether it is shared, driven by one subphenotype, or different between
subphenotypes.
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4.2.1.2 Separating Method
Identifying sources of unique pathophysiology is the goal of methods which separate subphe-
notypes into distinct groups for different analyses. In this approach, only genetic markers
that have a signal in the more homogeneous phenotype groups will be detected.
When the genetic markers are truly associated with both subphenotypes, the separating
approach will only detect association when the sample sizes are sufficient. In general, it is less
powered to detect shared effects than the pooled approach. Thus, only when the association
signal is strong (i.e., large effect) or the sample sizes very large, will the separate approach
detect any association shared between both subphenotypes. In the case when the increased
disease risk is unique to one subphenotype, the subphenotypes should be analyzed separately
to capture the distinction. Both modifier variants with varying degrees of increased risk in
both subphenotypes and those with opposite effects may be detected using this method,
although there would be no indication of the modifying nature of the locus.
A natural next step for this type of analysis is to compare the results from each of
the separate analyses. However, direct comparison of the resulting p-values from separate
analyses is not a valid method for examining heterogeneity, as p-values are dependent on
sample size and phenotypic distribution. Furthermore, qualitative comparison of p-values
and effect estimates does not give any information about potential differences between the
subphenotype specific analyses. Methods for comparing these results are discussed in the
summary-level tests section.
Similar to the pooled approach, it is feasible to perform separate analyses for subphe-
notypes with virtually any study design and statistical method, simply by changing the
phenotype definition.
4.2.1.3 Case-only Modifier Method
Unlike the two previous methods, which use all cases and controls in comparative analy-
ses, the case-only modifier directly compares allele frequencies of two subphenotype groups
without use of unaffected individuals. This provides a direct test of phenotypic differences
attributable to genetic heterogeneity. This analysis has high power to find genetic risk fac-
tors that differ between the two groups. Conversely, it will fail to detect any factors shared
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between both groups. Thus, this is strictly a test for heterogeneity of association between
genotype and phenotype; it is not a test of overall genetic effect. Ideally, this test will also
discover new loci for which there is only an effect in one subgroup (since the other subgroup
and controls are theoretically identical at this locus). As this method extracts cases from
the whole set of individuals being studied, it can be universally applied regardless of study
design.
4.2.1.4 Likelihood Method for Genome-wide Scans
Lee et al. propose a likelihood-based method to test for association, specifically to identify
any variants associated with phenotypic heterogeneity [37]. The purpose of this method is to
identify multiple types of modifying and subtype-specific variants from a genome-wide scan,
rather than improve power for detecting associations via genome-wide scans. This method
uses log-linear modeling to test for association in two stages. In the first stage, two models
(null and unstructured genetic effect) are compared using a two degree-of-freedom likelihood
ratio test. If, and only if, the first test is rejected at the prescribed level, the procedure
proceeds to stage two in which multiple models are compared using multiple information
criteria to identify exactly what effect the variant (which has already shown some level of
association with the unstructured genetic effect model) has on the disease. The models
considered in the second stage of the likelihood-based method are basic, subset, inv-subset,
general, and modifier which directly correspond to the five allele frequency possibilities for
phenotypic heterogeneity given in Figure 4.1.
After all of these models are fit in stage two, the AIC and BIC of the subtype-specific
models are compared. The model with the lowest AIC/BIC classifies the variant. Thus, this
approach can detect numerous types of variant associations genome-wide, including the three
primary types discussed. The authors do note that while this method is useful in identifying
many types of variants, it is not necessarily the most powerful technique for each specific
type of variant that may be present, as it employs two-stage testing.
Another potential issue with this likelihood-based approach is that it requires the speci-
fication of the population disease subtype frequency, s. If the value of s is misspecified, the
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correct variant model may not be chosen. This method also relies on log-linear modeling, so
it can only take independent cases and controls. However, extending this modeling approach
to accept case-parent trios or other combined data types is feasible using conditional logistic
regression or other maximum likelihood approaches.
4.2.1.5 Gene-by-Environment Method
In the case of family-based design (i.e. trios), genetic sources of phenotypic heterogeneity
were tested using the genotypic transmission disequilibrium test (gTDT) [70]. This method
uses cases and pseudo-controls in a conditional logistic regression framework. Pseudo-
controls are created from a trio consisting of two founders and one proband (i.e., affected
offspring). Using the genotypes of the founders, all possible genotypes of offspring are calcu-
lated. From this list of possible offspring genotypes, the observed genotype of the proband
is treated as a case while the unobserved genotypes are used as controls in a conditional
logistic regression. Similar to the standard TDT, only informative founder pairs are used for
analysis.
To investigate the heterogeneity in association results for two or more phenotypes, the
conditional logistic regression models are fit with interactions between genotype and pheno-
type case status. This provides a measure of association for the effect that case type has in
moderating the effect of genotype on affection status.
This method will theoretically identify genetic variants with differing effects between
subphenotypes, controlling for parental genotypes. However, this method requires the as-
sumption of a genetic model and has particularly low power to detect and subtype differences,
except in very common variants. Thus, it will be outperformed by other methods unless the
true underlying genetic model is known.
The technique can be performed on case-parent trios using the R package trio. It is not
extendable to any other data structure as the subtype indicator variable is defined at the
trio level.
47
4.2.2 Summary-level Tests
Individual genotype-level data is a gold standard for genetic associations, but frequently
only summary statistics from previous association scans are available. There are still useful
methods for detecting genetic sources of phenotypic heterogeneity that leverage summary
statistics. Furthermore, assessing heterogeneity after individual association scans provides
an intuitive and easy to use framework for detecting modifying and subtype-specific variants.
The three methods presented in the following section are capable of detecting subtype-
specific and modifier genetic variants as they compare the effect estimates from subtype-
specific analyses. It does not detect an overall association, i.e. shared variants. It is impor-
tant to note that the failure to detect a difference in two subphenotypes does not demonstrate
proof that the variant in question is shared between them both.
Summary-level tests are attractive as they can be performed post primary analyses and
do not require individual genotypes. Furthermore, they can be used for any statistical test,
provided it results in an effect estimate and corresponding standard error, and are not limited
to one study design. These methods are generally more flexible than the genotype-level tests.
4.2.2.1 Overlapping Confidence Intervals Method
A na¨ıve, but reasonable, approach to assessing heterogeneity is readily available through
summary statistics. Analyzing subgroups separately, one can obtain two effect estimates
and their corresponding confidence intervals. These resulting regions are represented by the
following:
Qˆ1 ± 1.96× ˆSE1
Qˆ2 ± 1.96× ˆSE2
The confidence intervals are then compared. Only if they are disjoint, is there said to
be any difference between the effects of the two subphenotypes. The significance level of
the confidence intervals can be changed to investigate the evidence of difference between
the two subphenotypes. One must be especially careful in the interpretation of visually
examining the overlap of confidence intervals. Non-overlapping confidence intervals indicate
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statistically significantly different point estimates, whereas overlapping confidence intervals
do NOT indicate non-significantly different point estimates.
4.2.2.2 Q Statistic Method
Unlike the visual inspection of confidence intervals, the Q statistic method provides statistical
framework for detecting differences in effect estimates [69].
This method is less conservative than the method of examining overlapping confidence
intervals, i.e. the overlapping confidence intervals method will reject a null hypothesis of no
association every time it is rejected via the Q statistic method, but the converse is not true
[69].
The difference in these two methods can be seen by examining the difference intervals.
Q statistic method:
(
Qˆ1 − Qˆ2
)
± 1.96
√(
ˆSE1
2
+ ˆSE2
2
)
Examining overlap method:
(
Qˆ1 − Qˆ2
)
± 1.96
(
ˆSE1 + ˆSE2
)
In both methods, the null hypothesis of no difference is rejected when the interval does
not contain 0. The difference between the Q statistic method and that of the overlapping
confidence intervals is the width of the interval: the interval from the overlapping method is
always larger than that of the Q statistic method.
The Q statistic method assumes that estimates are (1) consistent, (2) asymptotically
normal, and (3) asymptotically independent [69]. These requirements are typically satisfied
in the case of examining log odds ratios from two non-overlapping association scans, given
a large enough sample size.
4.2.2.3 Cochran’s Q Method
Cochrans Q is a test statistic for assessing heterogeneity of the effects of multiple studies in
a meta-analysis setting [14].
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The idea of detecting heterogeneity among two or more signals comes from meta-analysis.
One main assumption of meta-analysis is that the individual effects are homogeneous. If so,
the combined effect estimate is a true representation of the individual signals. Thus inter-
pretation of meta-analysis results depends on identifying heterogeneity, which is commonly
tested in a fixed-effects meta-analysis setting using Cochrans Q. This test seeks to find loci
for which the individual effects are heterogeneous. This approach is conservative, i.e. it has
low power to detect weak heterogeneity, especially when only two individual effects are being
tested.
There is also an extension of Cochrans Q for a random-effects meta-analysis; however,
in the context of orofacial clefting, we are looking at combining only two or three effects,
making a random-effects approach inappropriate. The same philosophical conclusions would
also hold for a random-effects test of heterogeneity.
Cochrans Q is calculated in the following way:
The pooled treatment effect is a weighted average of the individual treatment effects (e.g.
log odds ratios).
Tpooled =
∑
wiTi∑
wi
where wi =
1
SE(Ti)2)
The standard error of the pooled treatment effect is given by //
SE(Tpooled) =
1√∑
wi
The Cochran Q statistic is given by
Q =
k∑
i=1
wi(Ti − Tpooled)2
which follows a Chi-square distribution with k-1 degrees of freedom.
Cochrans Q statistic, which employs the pooled treatment effect, measures deviation
from a weighted average of two estimates. If there is large deviation, we reject the null
hypothesis that the effects are the same. This addresses a fundamentally different question
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than the one we ask when studying phenotypic heterogeneity. The pooled treatment effect
is assumed to be the true underlying genetic effect and only variants with enough distance
from this effect show evidence of heterogeneity. Although this formulation of this method
does not visually lend itself to the idea of detecting heterogeneity, it can be shown that for
the two subgroups, it is identical to the Q-statistic method. Thus, Cochrans Q provides an
extension of the Q-statistic method for more than three groups.
This method is applicable in any study design as it is a comparison of summary statistics
– it does not require genotype-level data. This method may also be used to compare more
than two subgroup estimates; however, it is underpowered to detect a difference in fewer
than 5 groups.
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Table 4.1: Comparison of the methods for testing genetic sources of phenotypic heterogeneity.
Method Type of variants detected Study Design Requirements
Pooled (p1 + p2) v. control shared genotype-level data
Separate p1 v. control, p2 v. control subtype-specific, modifier* genotype-level data
Case-only modifier p1 v. p2 modifier, subtype-specific* genotype-level data, cases only
Likelihood subtype-specific, modifier*, shared* genotype-level data, case-control
GxE modifier* genotype-level data, case-parent trios
Overlapping Confidence Intervals subtype-specific*, modifier* summary-level data
Q-statistic subtype-specific*, modifier* summary-level data
Cochrans Q subtype-specific*, modifier* summary-level data
* indicates that this method is not well-powered to find this type of variant
52
4.3 RESULTS
In order to demonstrate the properties and efficiency of the most commonly used methods
for detecting phenotypic heterogeneity, a toy simulation was performed. Genotypes were
randomly simulated assuming HWE and some true genetic model: (1) the risk was shared
equally among the two case subtypes (i.e. shared), (2) only one case subtype had increased
risk (i.e. subtype), (3) the risk increased linearly across the two case subtypes (i.e. gradient),
(4) the risk increased for one subtype and decreased for the other (i.e. opposite). The GRRs
under which these genotypes were simulated are summarized in Table 4.2.
Table 4.2: Genotypic relative risks for phenotypic heterogeneity demonstration.
Model
Genotypic Relative Risk
Controls Subtype 1 Subtype 2
Shared 1 3 3
Subtype 1 3 1
Modifier - gradient 1 1.5 3
Modifier - opposite 1.5 1 3
For the combined, separate and case-only modifier tests, genotypes of the two case sub-
types and controls were directly compared according to the prescribed statistical procedure.
Additionally, the two sets of results from the separate analysis for case subtype 1 and case
subtype 2 were compared using Cochran’s Q and the Q-statistic. The resulting p-values
from these association tests are given in Table 4.3.
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Table 4.3: Example performance of methods for testing genetic sources of phenotypic heterogeneity under multiple true models.
True Model
Analysis P-value
Combined Separate Modifier Cochran’s Q Q-statistic
type 1 v. control type 2 v. control
Shared 3.57× 10−29 3.82× 10−26 1.15× 10−22 3.80× 10−1 5.38× 10−1 5.38× 10−1
Subtype-specific 3.58× 10−15 6.42× 10−30 3.02× 10−1 8.39× 10−28 2.41× 10−11 2.41× 10−11
Modifier (gradient) 1.82× 10−15 2.67× 10−22 3.28× 10−5 6.93× 10−11 1.96× 10−4 1.96× 10−4
Modifier (opposite) 1.66× 10−2 3.67× 10−13 7.07× 10−6 1.25× 10−26 7.59× 10−16 7.59× 10−16
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Under the shared genetic model, the combined association clearly outperforms the
subtype-specific model. However, with this strong of a genetic effect, it is worthwhile to note
that both separate analyses demonstrate rather strong association signals. Appropriately,
the case-only modifier and comparison methods do not show evidence of statistically different
signals.
The performance of the various association tests under subtype-specific genetic model is
also expected; the separate analysis including only those cases with increased risk demon-
strated the most statistical significance; but the combined, case-only modifier, and summary-
level comparison approaches all detected association.
The gradient genetic model, in which there is increased risk for each subtype but one
subtype has increased risk over the other, may be the underlying genetic model that is not
completely obvious from the statistical results. In this situation, caution must be exercised in
interpreting the results from these multiple association scans. In this situation, examining the
GRRs and corresponding confidence intervals may be more illuminating that the association
test p-values.
When the effects for the two case subtypes are in the opposite direction, the case-only
modifier detects this difference most optimally, followed by the summary-level comparison
approaches. Notably in this situation, if the two subtypes were combined for analysis, no
association would be detected. This underscores the importance of examining phenotypic
heterogeneity not just within the top results from a combined analysis, but also from subtype
specific analyses.
4.4 DISCUSSION
There are many possible approaches to examine genetic sources of phenotypic heterogeneity
- each with it’s own advantages and disadvantages. Examining phenotypic heterogeneity can
be done using genotype-level data or summary-level data. As summary statistics are more
easily obtainable than genotype-level data, the summary-level tests can provide valuable
insight into the genetic architecture of complex traits. These methods tend to be more con-
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servative than the genotype-level test, but are useful when genotype level data is unavailable,
and when the true genetic model of risk loci is unknown.
Currently, the only method to assess genetic contributions to phenotypic heterogeneity
using case-parent trios at the genotype-level is the gene-by-environment framework, which
has very low statistical power and is not feasible for small sample sizes nor low-frequency
variants. In these situations, and in those with mixed data structures, summary-level meth-
ods, which can combined results from multiple analyses including those with different data
structures (with the assumption that the effects are the same), are invaluable.
Examining each of these methods together highlights the need for post-statistical testing
analysis. Without examining the estimated effects, the underlying genetic model will remain
obscured. It is the result of the phenotypic heterogeneity methods coupled with a depiction
of the effect estimates for each subtype that will paint a more comprehensive picture of the
statistical model of the genetic variants. Doing so may elucidate the biologic mechanism for
each risk locus, and in turn, further understanding of the genetic architecture of complex
traits.
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5.1 ABSTRACT
Background: Orofacial clefts (OFCs), including nonsyndromic cleft lip with or without cleft
palate (NSCL/P), are common birth defects. NSCL/P is highly heterogeneous with multiple
phenotypic presentations. Two common subtypes of NSCL/P are cleft lip (CL) and cleft
57
lip with cleft palate (CLP) which have different population prevalence. Similarly, NSCL/P
can be divided into bilateral and unilateral clefts, with unilateral being the most common.
Individuals with unilateral NSCL/P are more likely to be affected on the left side of the
upper lip, but right side affection also occurs. Moreover, NSCL/P is twice as common in
males as in females. The goal of this study is to discover genetic variants that have different
effects in case subgroups.
Methods: We conducted both common variant and rare variant analyses in 1,034 in-
dividuals of Asian ancestry with NSCL/P, examining four sources of heterogeneity within
CL/P: cleft type, sex, laterality, and side.
Results: We identified several regions associated with subtype differentiation – cleft
type differences in 8q24 (p=1.00 × 10−4), laterality differences in IRF6, a gene previously
implicated with wound healing (p=2.166 × 10−4), sex differences and side of unilateral CL
differences in FGFR2 (p=3.00 × 10−4, p=6.00 × 10−4), and sex differences in VAX1 (p<
1.00× 10−4) among others.
Conclusions: Many of the regions associated with phenotypic modification were either
adjacent to or overlapping functional elements based on ENCODE chromatin marks and
published craniofacial enhancers. We have identified multiple common and rare variants as
potential phenotypic modifiers of NSCL/P, and suggest plausible elements responsible for
phenotypic heterogeneity, further elucidating the complex genetic architecture of OFCs.
5.2 INTRODUCTION
Orofacial clefts (OFCs) are common birth defects, affecting approximately 1 in 800 births
worldwide [39]. Approximately 30% of OFCs are syndromic, occurring in combination with
some other structural, cognitive, or developmental anomalies. The remaining 70% of OFCs
occur as isolated (i.e. nonsyndromic) defects. Nonsyndromic OFCs have complex etiology
with multiple genetic and environmental factors interacting to influence risk.
Nonsyndromic OFCs are highly heterogeneous with multiple phenotypic presentations
[17]. OFCs are most commonly divided into three major subtypes: cleft lip (CL), cleft
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palate (CP), and cleft lip with cleft palate (CLP). CL and CLP share a defect of the lip
and are commonly combined for analyses as cleft lip with or without cleft palate (CL/P)
[21] [23]. CL/P and CP have historically been considered distinct disorders with separate
etiologies because of the different developmental origins of the lip and palate and markedly
different prevalence rates in males and females (CP is twice as common in females as in
males, while the opposite is true for CL/P [53]). However, they occasionally occur within
the same family, an event known as mixed clefting commonly observed in syndromic OFCs,
including Van der Woude syndrome [39].
The CL/P subgroup itself is quite heterogeneous and can be further subdivided into
bilateral and unilateral clefts, affecting either the left or right side of the upper lip. Of these,
left sided unilateral clefts are the most common and bilateral clefts are the least common [26].
The causes of variability in phenotype are largely unknown, and may arise due to underlying
genetic factors, different environmental exposures, or other unknown factors. There have
been many studies investigating the genetic architecture of NSCL/P, most collapsing cleft
subtypes into one larger group (primarily CL/P) for analysis [17] [39]. While this approach
is powerful to identify sources of genetic variation that contribute to overall NSCL/P, any
signal from genetic variation specific to only one subtype or that differentiates subtypes
will be masked. Very few studies have explored genetic associations for clefting phenotypes
beyond CL and CLP. There is some evidence that the 13q31 locus near SPRY2 has a stronger
effect in CLP [30] [46]. Similarly, variants in IRF6 are more strongly associated with CL
than CLP [52] [63]. Recent evidence suggests that GREM1 is associated with clefts in the
lip and soft palate [47]. Furthermore, variants in GRHL3 are associated with CP and not
with CL/P [42] [50] [78]. Examining CL/P subtypes may elucidate more of the complex
genetic architecture of OFCs by identifying genetic mechanisms that modify cleft subtype.
We hypothesized that genetic components of phenotypic heterogeneity, including any
contribution of rare variants, can be found for recognized clefting loci. We performed asso-
ciation tests for four sources of phenotypic heterogeneity within CL/P: cleft type (CL vs.
CLP), sex (male vs. female), laterality (unilateral vs. bilateral), and side (right unilateral
vs. left unilateral) in targeted sequencing from the CleftSeq study [40].
59
5.3 METHODS
5.3.1 Sample
We compared subtypes within clefting cases from the CleftSeq study to investigate the
potential genetic contribution to clefting heterogeneity. CleftSeq is a targeted sequencing
study of 13 previously reported loci associated with NSCL/P [40]. These 13 regions, totaling
6.3 Mb, were comprised of 9 high-priority candidates from previous GWAS and/or genome-
wide linkage studies and 4 regions containing candidate genes with prior evidence of rare
variants contributing to NSCL/P (Table 1.1). Sequencing was performed on 1,498 case-
parent trios from Europe, the United States, China and the Philippines.
From the 1,489 trios, we extracted 1,034 probands with NSCL/P of Asian (i.e. Chinese
or Filipino) ancestry for analysis and cross-classified them using the four clefting subtype
definitions (Table 5.1). Among the 1,034 cases, 33 with unknown laterality were excluded
from the analysis of laterality and side of cleft lip groups.
Table 5.1: Sample used for modifier analyses by population.
Cleft Type Sex Laterality Side of Cleft Lip
CL CLP Female Male Unilateral Bilateral Right Left
China 117 284 126 275 278 101 112 166
Philippines 171 462 219 414 440 182 147 293
Total 288 746 345 689 718 283 259 459
5.3.2 Common Variant Analysis
For each factor (i.e. cleft type, sex, laterality, and side), we performed a case vs. case
analysis, directly comparing allele frequencies at each SNP between the two groups (e.g. CL
vs. CLP, male vs. female, etc.). This type of analysis has very high power to find genetic
risk factors that differ between the two groups, but it has no power to find factors that
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are important in both groups. Thus this design is strictly a test for heterogeneity in the
genotype/phenotype relationship, not an overall test of genetic effect. Ideally, this test will
discover new loci for which there is an effect in only one subgroup; such loci may be masked
in an overall scan when groups are combined.
We analyzed the association between the four cleft subtype phenotypes and 19,982-20,089
common SNPs (MAF > 0.01) in the thirteen candidate regions by directly comparing the
two case subtypes using traditional Chi-Square tests for association. Each Asian population
(Chinese and Filipino) was analyzed separately to account for any population stratifica-
tion. Low-quality SNPs (missing genotypes > 5% or HWE p < 0.0001) were excluded from
analyses.
Inverse-variance effects-based meta-analysis of the two population-specific scans was per-
formed on 13,183-13,427 SNPs to detect any signal common to Asian populations. SNPs
were excluded from the meta-analyses if they were flagged as low-quality in at least one
population-specific analysis, or if effects were heterogeneous between populations (Cochrans
Q p < 0.05). Statistical significance was determined using a Bonferroni threshold adjusting
for four scans of thirteen regions of 9.615 × 10−4 (i.e. 0.05/52). This threshold allows for
the generation of hypotheses regarding the genetic mechanisms of clefting subtypes and thus
is not as strictly conservative as a Bonferroni correction for the number of markers tested
(5200 tests, p-value threshold of 1 × 10−5 [40]). Thus, the suggestive associations found in
this study should be followed up rigorously. Common variant analyses were performed using
PLINK software [61].
5.3.3 Rare Variant Analysis
Rare variants (MAF < 0.01) were also interrogated for association with subtype differentia-
tion using the same phenotype definitions as in the common variant analysis.
First, variants within exons of canonical transcripts of each gene were examined using
gene-based versions of the Collapsed Multivariate and Combining (CMC) test [44] and the
Sequence Kernel Association Test (SKAT) [82].
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Secondly, two window-based approaches were used to investigate burdens of all rare
variants. SNPs were combined into regions using two window-based methods – 2,662 windows
using a fixed window size of 5Kb with 2.5Kb overlap between windows, and 14,232 windows
using exactly 20 SNPs per window with 10 SNP overlap between windows (windows at
the end of each region contained at least 14 SNPs). Each window was comprised of SNPs
from only one of the candidate regions. Windows are highly correlated within each candidate
region, so statistical significance was again determined using a Bonferroni threshold of 9.615×
10−4. Rare variants were analyzed with the SKAT option in RVTESTS software [83].
5.3.4 Functional Annotation of Rare Variant Windows
The CleftSeq project sequenced 6.3Mb of largely non-coding DNA around these GWAS
and OFC candidate genes. We failed to identify significant associations in analyses of coding
variants (results not shown), so we hypothesized that functional variants would be regulatory.
We examined intervals containing overlapping windows for functional elements based on
ENCODE chromatin marks [15] [67] and published craniofacial enhancers [3] [10] [62].
5.4 RESULTS
5.4.1 Cleft Type
In the common variant meta-analysis, 20 SNPs from 4 loci were significantly associated with
CL v. CLP differentiation (Figure 5.1A). These associations were seen in SNPs on 9q22 near
PTCH1 and FOXE1, on 17p22 near NOG, and on 20q12 near MAFB. Specifically, a set of
variants in and near PTCH1 were more strongly associated with CL than with CLP (lead
SNP: rs202111971 p = 6.484×10−4, Figure 5.1B). A neighboring set of variants did not show
formally significant differences by cleft type, but tended to be more strongly associated with
CLP (Figure 5.1B). In the 9q22 region, a set of SNPs downstream of the FOXE1 transcription
start site were more strongly associated with CLP than with CL (lead SNP: rs73492791 p =
1.138× 10−4, Figure 5.1C). Moreover, minor alleles in the 17p22 regions and 20q12 regions
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were more strongly associated with CLP (lead SNPs: rs7208145 p = 9.041×10−4, rs6129626
p = 5.039 × 10−4, Figure 5.1C,E). Notably, none of these SNPs associated with cleft type
differentiation (CL vs. CLP) was significantly associated with risk of OFC overall [40].
Twenty-five windows of rare variants in the PAX7, ARHGAP29, 8q24, FOXE1, VAX1,
NTN1, and NOG sequencing regions were significantly associated with cleft type differentia-
tion (CL vs. CLP) (Table D1). Of these, two sets of three overlapping windows (8:129790677-
129795772 [min p = 4.50×10−4] and 8:130298273-130305772 [min p = 1.00×10−4]) on 8q24
are particularly interesting because they contain SNPs that individually show strong as-
sociation with NSCL/P in Europeans. Furthermore, one of these intervals (8:129790677-
129795772) consisting of three overlapping windows was located adjacent to a putative
regulatory element as defined by H3K27Ac marks in multiple cell types from ENCODE
(Figure 5.4A).
5.4.2 Laterality
In the common variant meta-analysis, 27 SNPs from 2 loci were significantly associated with
laterality differences (Figure 5.2A). These associations were seen for 26 SNPs on 1q32 near
IRF6 (lead SNP: rs6540559 p = 2.166× 10−4, Figure 5.2B) and a single SNP on 17p22 near
NOG (rs184942776 p = 5.262 × 10−5, Figure 5.2C). SNPs in IRF6 were associated with
differentiation between bilateral and unilateral CL/P. Specifically, minor alleles of SNPs
in IRF6 were associated with unilateral CL/P. The minor alleles at these SNPs also are
significantly protective against overall OFC risk (Table D5).
Differences in CL/P laterality were observed in 17 windows of rare variants (Table 5.1).
Despite having many overlapping windows of rare variants, there was no evidence of known
regulatory or enhancer elements within these intervals.
5.4.3 Sex
While no significant associations for sex differences were observed in the common variant
analysis (Figure 5.3A), 28 windows of rare variants were significantly associated with sex
differences (Table D3).
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Eight windows defining three larger intervals (10:118624030-118629029 [min p = 5.00×
10−4], 10:118638519-118644029 [min p < 1.00 × 10−4], and 10:118851530-11885725 [min p
< 1.00 × 10−4]) near VAX1 were significantly associated with sex differences in Filipinos.
One of these intervals (10:118851530-11885725), comprised of three windows near VAX1,
overlapped a craniofacial regulatory element identified from p300 ChIP-Seq in craniofacial
tissue in mouse embryos [3] [77] (Figure 5.4B). It is unclear what gene is regulated by this
element, as the activity pattern of the enhancer resembles the endogenous expression of both
adjacent genes VAX1 and SHTN1 [2] [16]. Interestingly, other significant windows in this
region occurred immediately downstream of SHTN1.
Two non-overlapping windows near FGFR2 (10:123368869-123373868 [p = 3.00× 10−4]
and 10:123479803-123483275 [p = 8.00 × 10−4]) were also significantly associated with sex
differences in Filipinos. The first of these windows overlapped multiple regulatory annota-
tions including a binding site for p63, a transcription factor known to regulate FGFR2 [20]
[22] (Figure 5.4C). The second window overlaps more regulatory annotations characteristic
of epithelial enhancers (Figure 5.4C).
5.4.4 Side of Lip
We did not observe any significant associations with right unilateral vs. left unilateral CL/P
in the common variant analysis (Figure 5.3B). However, 13 windows of rare variants were
significantly associated with side of cleft lip differentiation (Table D4). Interestingly, one
window near FGFR2 (10:123431369-123436368 [p = 6.00×10−4]) was significantly associated
with side of cleft lip differentiation in Filipinos and was adjacent to active enhancers from
human neural crest cell lines and a putative palate enhancer from p300 ChIP-seq of mouse
palatal tissue (Figure 5.4C).
64
AR
HG
AP
29
PAX
7
IRF
6
MS
X1 8q2
4
PTC
H1
FO
XE
1
FG
FR
2
VAX
1
BM
P4
NT
N1 NO
G
MA
FB
A
rs73492791
rs6129626
rs7208145rs202111971
B C
ED
Figure 5.1: CL vs. CLP cleft type modifiers. (A) Cleft type (CL vs. CLP) association
results from the common-variant meta-analysis of Filipino and Chinese populations. (B)-
(E) Regional association plots for 9q22 (x2), 17q22, and 20q12 showing log10(P-values)
for SNPs with stronger association with CL (squares) and stronger association with CLP
(circles) based on the direction of the odds ratio. Plots were generated using LocusZoom
[60]. The recombination overlay (blue line, right y-axis) indicates the boundaries of the
LD-block. Points are color coded according to pairwise linkage disequilibrium (r2) with the
index SNP.
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Figure 5.2: Unilateral vs. bilateral CL/P modifiers. (A) Laterality (unilateral vs. bilat-
eral) association results from the common-variant meta-analysis of Filipino and Chinese
populations. (B) Regional association plots for 1q32 showing log10(P-values) for SNPs with
stronger association with unilateral CL/P (squares) and stronger association with bilateral
CL/P (circles) based on the direction of the odds ratio. (C) Regional association plots
for 17q22 showing log10(P-values) for SNPs with stronger association with unilateral CL/P
(squares) and stronger association with bilateral CL/P (circles) based on the direction of the
odds ratio. Plots were generated using LocusZoom [60]. The recombination overlay (blue
line, right y-axis) indicates the boundaries of the LD-block. Points are color coded according
to pairwise linkage disequilibrium (r2) with the index SNP.
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Figure 5.3: Sex-specific modifiers of CL/P. (A) Sex (male vs. female) association results
from the common-variant meta-analysis of Filipino and Chinese populations. (B) Side (right
unilateral vs. left unilateral) association results from the common-variant meta-analysis of
Filipino and Chinese populations.
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Figure 5.4: Significant rare variant windows with potential regulatory effects. (A) 8q24 for cleft type, (B) VAX1 for sex, and
(C) FGFR2 for sex and side.
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5.5 DISCUSSION
NSCL/P is a complex disorder with many different anatomical forms. GWASs have identified
dozens of genetic associations with NSCL/P [4] [41] [46] [49]; however, a small number of
studies have identified cleft subtype specific associations, most of which are reflect differences
between CL and CLP [46] [52] [63]. The current study adds to these findings by identifying
both common and rare variants that are associated with subtype differentiation in cleft type,
laterality, sex, and side of unilateral CL. We performed common and rare variant association
testing with four cleft subtypes (cleft type: CL vs. CLP; laterality: unilateral vs. bilateral;
sex; and side: right vs. left CL/P) to further interrogate OFC-associated regions from
the CleftSeq targeting sequencing study. We identified several regions associated with cleft
subtype differentiation – common variants in IRF6 and rare variants in 8q24, FGFR2, and
VAX1, among others. Notably, these associations are found with both previously known
clefting-associated variants and variants that were not significantly associated with overall
clefting (CL/P). Multiple associations with regulatory (non-coding) elements and differences
in clefting subtypes were discovered, contributing to the evidence that non-coding variants
have a significant role in the genetic causes of NSCL/P [39] [40] [63]. However, it is not
clear from the association results which alleles are relevant to these phenotypes; systematic
studies in model systems will likely be required to identify functional SNPs and a possible
mechanism.
We identified 26 SNPs within IRF6 associated with differences between unilateral and
bilateral CL/P. Specifically, individuals with unilateral CL/P had higher frequencies of minor
alleles in these 26 variants than did bilateral CL/P individuals. IRF6 has been previously
implicated in wound healing [8] [7] [32], so these cleft laterality differences are particularly
interesting. The same alleles showing a protective effect for overall cleft risk were more
strongly associated with unilateral CL/P than bilateral. If we consider unilateral CL/P as
a less severe presentation of clefting than bilateral CL/P, our finding that OFC-protective
variants are associated more strongly with unilateral CL/P and previous evidence that IRF6
is associated with CL [63] together suggest that the IRF6 locus is associated with decreased
risk of severe clefting.
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Rare variants on 8q24 were found to significantly differ between CL and CLP, including
an interval adjacent to a putative regulatory element. This provides strong evidence for
a regulatory role of variants within 8q24 on the presentation of NSCL/P. Furthermore,
SNPs on 8q24 have previously shown very strong association with cleft risk in European
GWAS [5] [9] [24] [55], but are not associated with cleft risk in Asian GWAS(i.e. in common
variant analyses). This may be due to population-specific differences in SNP informativeness
within 8q24, which reflects haplotype diversity [55]. SNPs within 8q24 have markedly higher
heterozygosity in Europeans than Asians, making common-variant associations within this
region far more powerful among Europeans. We hypothesize that this region also is associated
with clefting risk in other populations, although the statistical evidence from analyses of
common variants is lacking. The association with cleft type differentiation within windows
of 8q24 rare variants observed in the Filipino population here may be evidence that some
SNPs within 8q24 confer clefting risk in Asian populations.
Additionally, rare variant associations with potential regulatory elements were observed
when examining sex differences and markers near VAX1 and FGFR2 and those near FGFR2
and the left vs. right side of unilateral CL/P. While it is not immediately clear how VAX1 and
FGFR2 specifically contribute to sex differences in NSCL/P, biological hypotheses regarding
sex differences in other disorders (e.g. autism) involve a multiple-threshold multifactorial
liability model in which females have a higher threshold than males. In other words, affected
females are hypothesized to carry a higher mutational burden than affected males. The
same would hold for NSCL/P, where there are more affected males than females. Under this
hypothesis, relatives of affected females are at increased risk for CL/P, which is supported by
population-based recurrence risk estimates from Denmark [25]. A similar threshold model
may also pertain to differences in laterality and severity of NSCL/P.
Contrary to the common disease-common variant hypothesis, we observed clear contri-
butions from both common and rare variants in this study of the genetic underpinnings
of NSCL/P and the potential differences within NSCL/P subtypes. This work adds to a
growing body of evidence implicating rare variants in risk of NSCL/P [1] [38] [40]. Impor-
tantly, this work highlights the impact of rare variants as potential phenotypic modifiers,
an area that needs larger studies in additional populations that are expanded to the entire
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genome. As costs of whole genome sequencing decrease, these studies will be more feasible
for NSCL/P and will continue to improve our understanding of the genetic architecture of
NSCL/P.
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6.1 INTRODUCTION
Orofacial clefting is a common complex birth defect with multiple phenotypic presentations.
OFCs can arise when there is a disruption in fetal craniofacial development, approximately
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during weeks four through ten of embryogenesis [17]. The upper lip and primary palate are
formed by the sixth week and the secondary palate is formed by the tenth week [17]; any
disruption in these processes many results in an orofacial cleft. Numerous genetic studies (in-
cluding genome-wide linkage and association) have made substantial progress in identifying
genetic risk factors for OFCs in the past decade.
The primary focus of the OFC genetics literature has been on the two most common
presentations: cleft lip with or without cleft palate (CL/P) and isolated cleft palate (CP)
[17] [39]. CL/P and CP have historically been considered distinct disorders due to the
different developmental origins of the lip and palate [31], different prevalence rates among
males and females [53], and different proportions of syndromic cases (50% CP vs. 30% for
CL/P) [39]. At least 20 genetic risk loci have been identified for CL/P [43]; only one locus
has been identified for CP [42]. Despite this progress, the identified risk loci only account
for a modest portion of the genetic variance of OFCs, suggesting that additional genetic risk
factors may be involved.
In the current study, we sought to identify additional genetic risk variants for specific
OFC subtypes - CL, CLP and CP - including exploring the possibility of shared etiology
between two or more subtypes. To do so, we conducted genome-wide meta-analyses for CL,
CLP, and CP using two large OFC studies.
6.2 METHODS
6.2.1 Contributing GWAS studies
Two consortia contributed to this study (Table 6.1). The first, hereafter called GENEVA
OFC, used a family-based design and included 461 case-parent trios with CL, 1143 case-
parent trios with CLP, and 451 case-parent trios with CP, from populations in Europe
(Denmark and Norway), the United States, and Asia (Singapore, Taiwan, Philippines, Ko-
rea, and China). The specifics of this study were previously described in [4] [5]. Briefly,
samples were genotyped for 589,945 SNPs on the Illumina Human610-Quadv.1 B Bead-
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Chip, genetic data were phased using SHAPEIT, and imputation was performed with IM-
PUTE2 software to the 1000 Genomes Phase 1 release (June 2011) reference panel. Geno-
type probabilities were converted to most-likely genotype calls with the GTOOL software
(http://www.well.ox.ac.uk/ cfreeman/software/gwas/gtool.html), using a genotype proba-
bility threshold of 0.9.
The second consortium included samples contributing to the Pittsburgh Orofacial Cleft
(POFC) study, comprising 179 cases and 271 case-parent trios with CL, 644 cases and 1048
case-parent trios with CLP, 78 cases and 165 case-parent trios with CP, plus 1700 unaffected
controls. Participants were recruited from 13 countries in North America (United States),
Central or South America (Guatemala, Argentina, Colombia, Puerto Rico), Asia (China,
Philippines), Europe (Denmark, Turkey, Spain), and Africa (Ethiopia, Nigeria). Additional
details on recruitment, genotyping, and quality controls are described in [41] [42]. Briefly,
samples were genotyped for 539,473 SNPs on the Illumina HumanCore + Exome array.
Data were phased with SHAPEIT2 and imputed using IMPUTE2 to the 1000 Genomes
Phase 3 release (September 2014) reference panel and converted to most-likely genotypes for
statistical analysis.
A total of 412 individuals were in both the GENEVA OFC and POFC studies, so we ex-
cluded these participants from the GENEVA OFC study for this analysis. Informed consent
was obtained for all participants and all sites had both local IRB approval and approval at
the University of Pittsburgh, the University of Iowa, or Johns Hopkins University.
Table 6.1: Counts of Cases, Controls, and Trios from the POFC and GENEVA studies.
Study
CL CLP CP
Controls Trios Cases Trios Cases Trios Cases
POFC 1700 271 179 1048 644 165 78
GENEVA – 461 – 1143 – 451 –
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6.2.2 SNP selection
Quality control procedures were completed in each contributing study and have been de-
scribed extensively in the original publications [41] [42] [4] [5]. In the POFC study, SNPs
with minor allele frequencies (MAF) less than 1% or those deviating from HWE (p<0.0001)
in genetically defined, unrelated European controls were excluded.
Similarly, SNPs with MAF <1% or those deviating from HWE were excluded. To ac-
count for different marker sets and identifiers between the two imputed datasets, the final
analysis included only those overlapping SNPs that were matched on chromosome, nucleotide
position, and alleles. A total of 6,090,031 SNPs were included in the meta-analysis.
6.2.3 Statistical Analysis
We identified three analysis groups from the contributing studies: a case-control subgroup
from POFC, an unrelated case-parent trio group from POFC, and an unrelated case-parent
trio group from GENEVA OFC. In the casecontrol subgroup, logistic regression was used to
test for association under the additive genetic model, while including 18 principal components
of ancestry (generated via principal component analysis [PCA] of 67,000 SNPs in low linkage
disequilibrium across all ancestry groups) to adjust for population structure [41]. The two
case-parent trio subgroups from POFC and GENEVA were analyzed separately using the
TDT. The resulting effect estimates for the three analysis groups were combined in an
inverse variance-weighted fixed-effects meta-analysis. The combined estimate, a weighted
log odds ratio, was compared to a Chi-squared distribution with two degrees of freedom.
This procedure was followed for three GWASs, one for each cleft type.
From these three scans, SNPs demonstrating suggestive association (i.e. p < 1.00×10−5)
in any of the three scans were considered for further analysis. For each SNP, the effects of
CL were compared to those of CLP, and the effects of CLP compared to those of CP using
the Q-statistic [69]. These two contrasts were chosen based on the biologic plausibility of
shared genetic effects between clefts affecting the lip (CL and CLP) and clefts affecting the
palate (CLP and CP). A strict statistical significance threshold was set at 8.6 × 10−4 [(i.e.
0.05/(29 ∗ 2)], but results were also considered for suggestive evidence. The goal of this
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method was to examine the results holistically to gain further understanding of cleft-specific
signals. Further, the direction of association was determined by the difference in absolute
values of the log odds ratios (i.e. |log(ORCLP )|−|log(ORCL)|, |log(ORCLP )|−|log(ORCP )|).
This set of 1,375 SNPs was collapsed into 29 loci based on genomic position and linkage
disequilibrium. Loci spanning large regions with evidence of multiple, statistically indepen-
dent signals (i.e. IRF6 and 8q24) were subdivided into multiple groups of SNPs based on
LD grouping in PLINK software [41] [61]. The p-values comparing CL to CLP and CLP to
CP were averaged across the SNPs within a locus. Similarly, the direction of association for
CL to CLP and CLP to CP was averaged across the SNPs within a locus. The sign of this
average direction indicated the cleft type with the strongest association signal for that locus.
These loci were then represented graphically on what is hereinafter referred to as the cleft
map. The x-axis on the cleft map is given by the average log10 p-value of the comparison
between CL and CLP of the locus times the sign of the average direction (CLP or CL) of the
locus. The y-axis of the cleft map is given by the average log10 p-value of the comparison
between CLP and CP of the locus times the sign of the average direction (CLP or CP) of
the locus. Thus, loci nearest the origin do not demonstrate any subtype-specific signals in
our sample. Loci along the x-axis in the left half of the map demonstrate evidence for CL-
specific association; loci along the y-axis in the lower half of the map demonstrate evidence
for CP-specific association; loci in the upper-right quadrant demonstrate evidence for CLP-
specific association; loci along the y-axis in the upper half of the map demonstrate evidence
for CL/P-specific association. A summary of this is represented in Figure 6.1. Loci further
away from the origin exhibit more statistical evidence of cleft-specific signals. Concentric
circles about the origin based on log10 p-values of the Q-statistics are given for reference.
Also, the size of the point on the map represents the strength of association in the separate
GWASs.
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Figure 6.1: Guide to interpret cleft subtype-specific signals
6.3 RESULTS
In our comparison of the effects for CL, CLP, and CP for 29 loci with marginal associ-
ation for at least one subtype, we identified many loci with stronger association in one
cleft subtype in addition to a handful of loci demonstrating no evidence of subtype-specific
signals. Specifically, two genes (UGT3A2 and GRHL3 ) show evidence of CP-specific asso-
ciation (average p-values: (pCLP.CL = 0.93, pCLP.CP = 8.9 × 10−5) and (pCLP.CL = 0.64,
pCLP.CP = 2.2 × 10−5) respectively). We also identified two possible CL-specific asso-
ciations in SLC28A3 and possibly COL8A1 (average p-values: (pCLP.CL = 4.1 × 10−5,
pCLP.CP = 0.24) and (pCLP.CL = 4.9 × 10−3, pCLP.CP = 0.011) respectively). WNT5A and
MSX2 are among a few genes demonstrating CLP-specific association (average p-values:
(pCLP.CL = 9.8× 10−5, pCLP.CP = 0.073) and (pCLP.CL = 3.8× 10−3, pCLP.CP = 3.7× 10−4)
respectively). Further, many loci including known CL/P risk genes with substantial evidence
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(IRF6a,b and 8q24a,b,c gene desert) appear in the combined CL and CLP area (average p-
values shown in Table 6.2).
A brief summary of the findings is given in this Table 6.2.
Table 6.2: Average p-values from the Q-statistic comparison of CLP to CL, and CLP to CP
for each locus.
Locus # SNPs PCLP.CL PCLP.CP Locus # SNPs PCLP.CL PCLP.CP
PAX7 60 0.084 0.056 FOXE1 36 0.67 0.25
CAPZB 21 0.065 2.1× 10−3 VAX1 41 0.58 0.26
GRHL3 17 0.64 2.2× 10−5 KRT18 7 0.18 4.5× 10−5
ARHGAP29 26 0.79 0.031 SPRY2 15 0.16 2.3× 10−4
WNT5A 14 9.8× 10−5 0.073 ARID3B 148 0.82 7.6× 10−3
ERC2 18 0.064 0.23 NTN1 48 0.24 3.0× 10−3
COL8A1 226 4.9× 10−3 0.011 GOSR2 62 0.50 0.38
TP63 9 0.78 0.013 NOG 4 0.47 0.41
SHROOM3 36 0.95 6.3× 10−4 MAFB 46 0.22 0.011
UGT3A2 7 0.93 8.9× 10−5 IRF6a 126 0.81 6.2× 10−8
MSX2 20 3.8× 10−3 3.7× 10−4 IRF6b 60 0.063 3.0× 10−4
TRIM10 1 0.33 0.36 8q24a 136 0.57 3.0× 10−5
DCAF4L2 8 0.55 0.023 8q24b 117 0.78 3.1× 10−3
BAALC 5 0.012 0.14 8q24c 52 0.022 0.042
SLC28A3 9 4.1× 10−5 0.24
78
-log10(PCL.CLP)*sgn(DCL.CLP)
-l
o
g1
0
(P
C
P.
C
LP
)*
sg
n
(D
C
P.
C
LP
)
10−02
10−04
10−06
10−08
Figure 6.2: Cleft Map
6.4 DISCUSSION
This analysis comparing association signals from three GWAS of the primary cleft subtypes
(CL, CLP, and CP) detected numerous cleft-type-specific signals. These findings add to the
evidence that many OFC-risk genes operate in a way that may increase risk of one cleft
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type. Specifically, we have demonstrated that many known cleft-risk regions (e.g. IRF6
and the 8q24 gene desert) are common to CL/P as demonstrated by numerous GWASs.
Further, we note that GRHL3, which is the only gene implicated for isolated cleft palate
in a genome-wide association study, demonstrated a CP-specific signal in our analysis. We
also note that many candidate genes for OFCs (e.g. FOXE1 ) may generally increase risk of
clefting in a non-cleft-type-specific manner. Replication attempts for these and the rest of
the regions depicted in the ”map” are currently underway to compare our findings to those
using a similar procedure in a set of independent OFC cases and controls.
It is important to note the limitations of using statistical comparisons to identify these
cleft-type-specific signals. A failure to demonstrate a statistically significant signal for one
cleft type does not prove that the signal is common to all clefts. Further investigation of the
signals that appear to be common to OFCs in general, regardless of cleft type, should be
conducted.
Methods similar to the one proposed here are necessary to explain the system by which
OFCs occur. Identifying statistically different association signals among clefting subtypes
will be crucial in understanding the biologic systems through which OFCs develop. These
methods are fundamental to understanding difference in association signals from multiple
subtypes. The naive approach to compare results from separate analyses lacks statistical
rigor and is inappropriate. Statistical significance (i.e. p-values) are dependent upon sample
size and, as with most clefting studies, there is not perfect balance among the cases of
different cleft types; the naive approach (i.e. comparing p-values between association scans)
is unsuitable to detect differences.
This method of comparison may also be extended to study other subphenotypes in oro-
facial clefting or other complex traits. Specifically within clefting, the contribution of sub-
clinical phenotypes to the transmission of cleft-risk variants has been suggested, especially
in the case of the obicularis oris muscle defects [57]. Extending the subphenotype defini-
tions for OFCs to include the presence and absence of subclinical phenotypes may further
demonstrate the role of subclinical phenotypes in the OFC-transmission. Furthermore, this
method may be useful in untangling the mechanisms determining cleft severity, which can
be measured by the completeness of a cleft and whether one, or both, sides of the face
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is affected. The POFC study has detailed phenotyping for individuals with OFC, which
when accompanied with this method to distinguish specific signals, may further elucidate
the genetic mechanisms operating to form each specific cleft type.
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7.0 CONCLUSIONS
In this multifaceted dissertation, we examined two hallmarks of common, complex traits –
the analysis of mixed data structures and phenotypic heterogeneity – in a genome-wide asso-
ciation setting. For the analysis of mixed data structures, we provided an overview of existing
methods for combining data from case-parent trios and unrelated cases and controls and pro-
posed a new empirical Bayes-type shrinkage estimator for estimating genotypic relative risk
in mixed data structures. The application of these methods was also studied in an example
of a multiethnic study of orofacial clefts. Furthermore, we examined sources of phenotypic
heterogeneity in complex traits, and conducted a philosophical evaluation of existing statis-
tical methods capable of identifying genetic sources of phenotypic heterogeneity. We then
applied some of these tools to identify cleft subtype-specific signals in a targeted sequencing
study of orofacial clefting and to classify associated variants by which cleft types they are
associated with in the context of genome-wide meta-analysis. Through these investigations
we have provided insight into the statistical methods commonly employed to address mixed
data structures and phenotypic heterogeneity as well as the genetic architecture of orofacial
clefting.
7.1 STRENGTHS, LIMITATIONS, AND FUTURE WORK
7.1.1 Empirical Bayes-Type Estimator
The empirical Bayes-type estimator defined in chapter 3 demonstrated no gain in efficiency,
likely due to the use of a robust variance estimate, as the analytical variance of the estimator
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cannot be formulated. In general, empirical Bayes-type estimators are good ways to gain
efficiency even when assumptions are violated, but in this case the maximum likelihood esti-
mates were not tractable. Thus, this method requires a robust sandwich estimate of variance.
Notably, conservative estimates were also obtained for the constrained and unconstrained
estimators employing robust variance estimates.
As evidenced in the application to the multiethnic study of orofacial clefts, the empirical
Bayes-type estimator preserves the ranking of the most significantly-associated regions. This
demonstrates the utility of the empirical Bayes-type estimator, in that it appropriately orders
genetic variants by strength of association. Further simulation is warranted to investigate if
the preservation of ranked variants holds in general.
Additionally, the variance of the empirical Bayes-type estimator could be estimated em-
pirically through permutations. Using an permutation-based variance estimate may improve
the behavior of the association test by eliminating the overly conservative nature of the test
statistic. By using an empirical variance estimate, the resulting test statistic should more
closely follow a uniform distribution under the null hypothesis and improve the behavior
of the significance test. Thus, this empirical Bayes-type estimator proposed in chapter 3
may demonstrate practical importance to mixed data studies, as it preserves the order of
significant variants and could be improved through empirically estimated variance.
This method assumes an additive genetic model for each variant. This does not present a
problem in studying OFCs, as the majority of the variants discovered do not deviate severely
from an additive model. However, should other genetic models be desired, this method could
be extended to model them. This method currently assesses association for common variants
only; low-frequency variants are excluded because of the nature of the estimator. There are
existing rare variant methods that work for case-control and trios separately and SKAT for
larger families, but none that incorporates mixed data types [28] [73]. Development of a
similar, empirical Bayes-types estimator to assess a burden of rare variants would require
defining the constrained and unconstrained models; the notation of HWE across a set of
SNPs would need to be specified.
Many extensions of the TDT, which account for missing parental genotypes, an addi-
tional offspring, and affected parents exist. Currently, this method does not provide similar
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accommodations, but extensions may be feasible. Along those same lines, the only family-
based data this method takes is the case-parent trio. It may be beneficial to extend this
method to larger pedigrees by including them in the formation of the likelihood. This would
require specifying the exact nature of the likelihood, and would not necessarily account for
all familial relationships like some genome-wide association methods do.
This method does not adjust for principal components of ancestry or other covariates,
but rather assumes homogeneity of effects within the population being studied.
Lastly, the construction of the partial M-estimator assumes θˆ and VB are known quan-
tities. It could be adapted to incorporate the estimation of these parameters into the esti-
mating equations at the expense of computational time.
7.1.2 Phenotypic Heterogeneity
We explored many new aspects for detecting genetic differences for trait differences in com-
plex disease. We presented numerous statistical methods for detecting genetic variants as-
sociated with phenotypic heterogeneity, both for analyzing genotype-level data and for com-
bining summary-level results from multiple analyses. In doing so, we identified the situations
in which each method for detecting phenotypic heterogeneity is most optimal.
Additionally, in chapter 5, we determined specific genetic loci associated with differen-
tiating OFC subphenotypes in a targeted sequencing study. We observed both common
and rare variants contributing to the genetic underpinnings and subphenotype differences of
CL/P. Importantly, this work motivates the study of rare variants as potential phenotypic
modifiers.
Furthermore, we developed a novel visualization tool for displaying genetic risk factors
for OFCs in chapter 6. This tool presents statistical evidence for heterogeneity within a
risk locus by examining differences in effects between multiple subphenotypes of OFCs.
Particularly, this tool avoids the traditional dichotomization of statistical significance (i.e.
p-value < 0.05) but rather visualizes the statistical evidence of heterogeneity for each genetic
locus. From this visualization, we can motivate potential biologic mechanisms which may
drive the heterogeneous process through which OFCs arise.
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Future analyses examining phenotypic heterogeneity will include examining gene×gene
interactions between loci shown as potential modifiers with CL/P risk loci or general OFC
risk loci. Ideally, these potential interactions will motivate biological mechanisms underlying
the genetic association with OFCs.
The analysis of genetic sources of phenotypic heterogeneity may provide insight into
the mechanisms by which OFCs come about. Examining genetic sources of phenotypic
heterogeneity may be excellent for nominating possible biologic mechanisms/processes that
may be responsible for modifying phenotypes. Moreover, the methods and tools discussed
here can and should be applied to the study of other complex traits to advance understanding
of the genetic architecture of diverse traits across the phenotypic spectrum.
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APPENDIX A
TABLE OF ABBREVIATIONS
Table A1: Commonly-used abbreviations
GWAS Genome-wide association study
SNP single-nucleotide polymorphism
OFC orofacial cleft
CL isolated cleft lip
CLP cleft lip and palate
CL/P cleft lip with/without cleft palate
CP isolated cleft palate
NSCL/P nonsyndromic cleft lip with/without cleft palate
TDT transmission-disequilibrium test
CPG conditional on parental genotype
GRR genotypic relative risk
MAF minor allele frequency
HWE Hardy-Weinberg Equilibrium
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APPENDIX B
VARIANCE CALCULATION FOR THE EMPIRICAL BAYES-TYPE
ESTIMATOR
B.1 ROBUST SANDWICH ESTIMATE OF VARIANCE FOR
CONSTRAINED ESTIMATE
VN(βˆ
0) =
1
N
N∑
1
(f1i(β
0)xi + f2,gpi,i(β
0)(1− xi))2
(
xif
′
1i(β) + (1− xi)f ′2,gpi,i(β)
)2(
xif ′1i(β0) + (1− xi)f ′2,gpi,i(β0)
)2 (
xif ′1i(β) + (1− xi)f ′2,gpi,i(β)
)2 (B.1.1)
f1i =
(
N1i
p1i
)(
δp1i(β)
δβ
)
f2,gpi,i =
(
Ngpi,i
pgpi,i
)(
δpgpi,i
δβ
)
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B.2 ROBUST SANDWICH ESTIMATE OF VARIANCE FOR
UNCONSTRAINED ESTIMATE
VN(βˆ
0) =
1
N
N∑
1
(f1i(β)xi + f2,gpi,i(β)(1− xi))2
(
xif
′
1i(β
0) + (1− xi)f ′2,gpi,i(β0)
)2(
xif ′1i(β0) + (1− xi)f ′2,gpi,i(β0)
)2 (
xif ′1i(β) + (1− xi)f ′2,gpi,i(β)
)2 (B.2.1)
f1i =
(
N1i
p1i
)(
δp1i(β)
δβ
)
f2,gpi,i =
(
Ngpi,i
pgpi,i
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δpgpi,i
δβ
)
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B.3 ROBUST SANDWICH ESTIMATE OF VARIANCE FOR EMPIRICAL
BAYES-TYPE ESTIMATE
VN(βˆEB) =
1
N
N∑
1
(f1i(β
0)xi + f2,gpi,i(β
0)(1− xi))(−K(β − β0) + β − βEB)×(
Kxif
′
1i(β)−Kxif ′2,gpi,i(β) +Kf ′2,gpi,i(β)
)(
xif ′1i(β0) + (1− xi)f ′2,gpi,i(β0)
) (
xif ′1i(β) + (1− xi)f ′2,gpi,i(β)
)
+
(
Kxif
′
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)×
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0)(1− xi))(−K(β − β0) + β − βEB)(
xif ′1i(β0) + (1− xi)f ′2,gpi,i(β0)
) (
xif ′1i(β) + (1− xi)f ′2,gpi,i(β)
)+ (B.3.1)
f2,gpi,i(β
0)(1− xi))2
(
Kxif
′
1i(β)−K(1− xi)f ′2,gpi,i(β)
)(
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)2 (
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)2
−(K − 1)((f1i(β)xi + f2,gpi,i(β)(1− xi))(−K(β − β
0) + β − βEB))
xif ′1i(β) + (1− xi)f ′2,gpi,i(β)
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where f1i =
(
N1i
p1i
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δp1i(β)
δβ
)
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(
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δβ
)
and
K = Vˆβˆ(Vˆβˆ + θˆ
2∆ˆT ∆ˆ)−1
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APPENDIX C
SUPPLEMENTAL FIGURES
Figure C1: Regional association plot showing −log10(P − value) for genotyped SNPs at the
1p36 locus from the meta-analysis of the European-ancestry group
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Figure C2: Regional association plot showing −log10(P − value) for genotyped SNPs at the
6p21 locus from the meta-analysis of the European-ancestry group
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Figure C3: Regional association plot showing −log10(P − value) for genotyped SNPs at the
8q24 locus from the meta-analysis of the European-ancestry group
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Figure C4: Regional association plot showing −log10(P − value) for genotyped SNPs at the
17p13 locus from the meta-analysis of the European-ancestry group
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Figure C5: Regional association plot showing −log10(P − value) for genotyped SNPs at the
17q23 locus from the meta-analysis of the European-ancestry group
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APPENDIX D
SUPPLEMENTAL TABLES
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Table D1: Windows of rare variants with statistically significant association with cleft type
(CL vs. CLP).
Window Range Population Window Type P-value
1:18943576-18946340 Philippines 20 SNP 6.00E-04
1:18999691-19004690 Philippines 5 KB 6.00E-04
1:19000487-19002797 Philippines 20 SNP 4.00E-04
1:19002191-19007190 Philippines 5 KB 3.00E-04
1:19002383-19004086 Philippines 20 SNP 3.00E-04
1:19004691-19009690 Philippines 5 KB 9.00E-04
1:19005587-19007798 Philippines 20 SNP 5.00E-04
1:95007579-95012578 China 5 KB 2.00E-04
8:129790677-129793236 Philippines 20 SNP 8.00E-04
8:129790773-129795772 Philippines 5 KB 6.00E-04
8:129791975-129794554 Philippines 20 SNP 4.50E-04
8:130298273-130303272 Philippines 5 KB 1.00E-04
8:130300154-130302665 Philippines 20 SNP 2.50E-04
8:130300773-130305772 Philippines 5 KB 5.00E-04
9:100464682-100465908 China 20 SNP 2.00E-04
9:100487529-100492528 China 5 KB 3.00E-04
9:100680029-100685028 Philippines 5 KB 2.00E-04
9:100681080-100683520 Philippines 20 SNP 8.00E-04
10:118459030-118464029 Philippines 5 KB 7.00E-04
10:118653761-118655989 China 20 SNP 3.00E-04
10:118724030-118729029 Philippines 5 KB 6.00E-04
17:8998160-9001204 China 20 SNP 7.50E-04
17:9000016-9005015 China 5 KB 1.00E-04
17:9057516-9062515 China 5 KB 7.00E-04
17:54817004-54818659 China 20 SNP 8.00E-04
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Table D2: Windows of rare variants with statistically significant association with laterality
(unilateral vs. bilateral).
Window Range Population Window Type P-value
1:94925079-94930078 Philippines 5 KB 6.00E-04
1:94925714-94928273 Philippines 20 SNP 4.00E-04
1:94927110-94929746 Philippines 20 SNP 9.00E-04
1:94981785-94983950 Philippines 20 SNP 4.50E-04
8:129515829-129517924 Philippines 20 SNP 7.00E-04
8:129557483-129559460 China 20 SNP 6.00E-04
8:129575655-129577099 China 20 SNP 1.00E-04
8:129576195-129578952 China 20 SNP 4.00E-04
8:129888186-129889673 China 20 SNP < 0.0001
9:98133816-98138815 Philippines 5 KB 7.00E-04
9:98136401-98138871 Philippines 20 SNP 7.00E-04
9:98148816-98153815 China 5 KB 7.00E-04
9:98149174-98150718 China 20 SNP 1.00E-04
17:9234571-9236098 China 20 SNP 6.50E-04
17:54567773-54572772 China 5 KB 1.00E-04
20:39260700-39265699 China 5 KB 3.00E-04
20:39264089-39265758 China 20 SNP 1.00E-04
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Table D3: Windows of rare variants with statistically significant association with sex (male
vs. female).
Window Range Population Window Type P-value
1:19198100-19199678 Philippines 20 SNP 2.00E-04
1:19199721-19200817 Philippines 20 SNP 7.00E-04
1:94327579-94332578 China 5 KB 5.00E-04
1:94328844-94331028 China 20 SNP 5.00E-05
1:94342579-94347578 China 5 KB 9.00E-04
1:94385079-94390078 China 5 KB 8.00E-04
4:4876429-4878242 China 20 SNP 9.50E-04
8:130028642-130030604 China 20 SNP 3.50E-04
9:100697529-100702528 Philippines 5 KB 9.00E-04
9:100697713-100700826 Philippines 20 SNP 9.00E-04
10:118541530-118546529 Philippines 5 KB 3.00E-04
10:118596325-118598622 Philippines 20 SNP 4.00E-04
10:118624030-118629029 Philippines 5 KB 5.00E-04
10:118625260-118628030 Philippines 20 SNP 7.00E-04
10:118638519-118640461 Philippines 20 SNP 1.00E-04
10:118639030-118644029 Philippines 5 KB 2.00E-04
10:118639485-118641706 Philippines 20 SNP < 0.0001
10:118851530-118856529 Philippines 5 KB 2.00E-04
10:118854083-118856514 Philippines 20 SNP < 0.0001
10:118854900-118857525 Philippines 20 SNP 1.00E-04
10:123368869-123373868 Philippines 5 KB 3.00E-04
10:123479803-123483275 Philippines 20 SNP 8.00E-04
17:54615714-54618317 China 20 SNP 6.00E-04
17:54766942-54767309 Philippines 20 SNP 9.50E-04
17:54811309-54812853 Philippines 20 SNP 4.00E-04
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Table D3 (continued)
Window Range Population Window Type P-value
20:39291288-39293331 China 20 SNP 9.00E-04
20:39444857-39446029 China 20 SNP 1.00E-04
20:39445740-39446718 China 20 SNP 6.00E-04
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Table D4: Windows of rare variants with statistically significant association with side (uni-
lateral left vs. unilateral right).
Window Range Population Window Type P-value
1:19044691-19049690 Philippines 5 KB 3.00E-04
1:19044786-19046526 Philippines 20 SNP 2.50E-04
1:94745898-94747471 China 20 SNP 8.00E-04
1:94860079-94865078 Philippines 5 KB 7.00E-04
1:94861794-94864557 Philippines 20 SNP 5.00E-04
9:98306107-98308002 Philippines 20 SNP 6.50E-04
9:100631558-100633036 Philippines 20 SNP 5.00E-04
9:100652529-100657528 China 5 KB 9.00E-04
10:123431369-123436368 Philippines 5 KB 6.00E-04
17:54567379-54569266 Philippines 20 SNP 2.00E-04
17:54567773-54572772 Philippines 5 KB 6.00E-04
17:54568409-54570881 Philippines 20 SNP 4.00E-04
20:39231214-39232819 Philippines 20 SNP 7.00E-04
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Table D5: Modifier association results for laterality (unilateral vs. bilateral) and TDT results for NSCL/P for variants within
IRF6.
CHR SNP BP Minor Allele Major Allele OR (modifier) P-value (modifier) OR (TDT) P (TDT)
1 rs4844895 209958580 C T 0.6869 8.32E-04 0.6541 2.34E-10
1 rs2235372 209960436 A G 0.6753 6.46E-04 0.6558 9.56E-10
1 rs742214 209960925 C T 0.6899 9.13E-04 0.6697 1.78E-09
1 rs742215 209961023 A T 0.6896 9.06E-04 0.6721 2.56E-09
1 rs2073485 209962794 A G 0.6891 8.89E-04 0.6697 1.97E-09
1 rs2235373 209963803 A G 0.6766 5.18E-04 0.6613 5.96E-10
1 rs2235375 209965587 C G 0.691 5.91E-04 0.6912 1.44E-08
1 rs6685182 209968319 A C 0.698 8.31E-04 0.6973 3.35E-08
1 rs2013162 209968684 A C 0.6869 4.84E-04 0.6954 2.48E-08
1 rs2236907 209971628 A C 0.6947 7.18E-04 0.6991 4.10E-08
1 rs2236908 209971640 C G 0.6872 5.07E-04 0.6907 1.39E-08
1 rs2236909 209971655 G A 0.6917 6.15E-04 0.6972 3.03E-08
1 rs2294408 209973549 A G 0.7005 9.52E-04 0.6943 2.32E-08
1 rs2073486 209976215 A G 0.6837 4.22E-04 0.6872 9.20E-09
1 rs2073487 209976646 C T 0.6776 3.07E-04 0.6942 2.09E-08
1 rs17015250 209978777 G T 0.6887 5.19E-04 0.6888 1.02E-08
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Table D5 (continued)
CHR SNP BP Minor Allele Major Allele OR (modifier) P-value (modifier) OR (TDT) P (TDT)
1 rs12403599 209979014 C G 0.6895 5.52E-04 0.6831 5.83E-09
1 rs7545538 209979613 G C 0.6832 4.16E-04 0.6912 3.05E-08
1 rs7545542 209979635 T C 0.6744 2.75E-04 0.6774 3.63E-09
1 rs2357229 209980489 T G 0.6801 3.85E-04 0.6798 5.18E-09
1 rs1005287 209980757 A G 0.6928 6.48E-04 0.6849 7.20E-09
1 rs6540559 209982025 A G 0.6572 2.17E-04 0.6606 7.01E-10
1 rs6696825 209982372 G A 0.6715 3.80E-04 0.6679 1.42E-09
1 rs6659367 209982408 T G 0.6649 3.00E-04 0.6667 1.97E-09
1 rs764093 209983331 G A 0.6765 4.77E-04 0.6631 6.77E-10
1 rs12070337 209992127 A G 0.6901 8.82E-04 0.6679 1.42E-09
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